ciprofloxacin has been researched along with Disease Models, Animal in 278 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In August 2000, the US Food and Drug Administration (FDA) approved ciprofloxacin hydrochloride (Cipro; Bayer) for management of postexposure inhalational anthrax." | 8.82 | US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax. ( Albrecht, R; Dionne, P; Higgins, K; Meyer, JM; Meyerhoff, A; Murphy, D, 2004) |
| "In the clindamycin group, 8 of 11 (73%) survived demonstrating its efficacy for the first time in inhalational anthrax, compared to 9 of 9 (100%) with ciprofloxacin, and 8 of 11 (73%) with ciprofloxacin + clindamycin." | 8.02 | Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin. ( Barr, JR; Boyer, AE; Chabot, DJ; Cote, CK; Fetterer, DP; Friedlander, AM; Ingavale, S; Klimko, CP; Miller, JA; Schellhase, CW; Somerville, BC; Tobery, SA; Twenhafel, NA; Vietri, NJ; Woolfitt, AR; Wright, ME, 2021) |
| "The in vivo efficacy of liposomal encapsulated ciprofloxacin in two formulations, lipoquin and apulmiq, were evaluated against the causative agent of anthrax, Bacillus anthracis." | 7.96 | Evaluation of liposomal ciprofloxacin formulations in a murine model of anthrax. ( Blanchard, JD; Crichton, M; Jager, S; Stratilo, CW, 2020) |
| "Ciprofloxacin and levofloxacin, 2 fluoroquinolone antimicrobials, are ≥90% effective for the treatment of inhalational plague when administered within 2-6 hours of fever onset in African green monkeys (AGM)." | 7.96 | Effect of Delaying Treatment on Efficacy of Ciprofloxacin and Levofloxacin in the African Green Monkey Model of Pneumonic Plague. ( Campbell, JL; Fay, MP; Hewitt, JA; Lanning, LL, 2020) |
| "To evaluate the efficacy of a fixed-dose combination of two approved drugs, Ciprofloxacin and Celecoxib, as a potential therapeutic treatment for amyotrophic lateral sclerosis (ALS)." | 7.96 | Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis. ( Armstrong, GAB; Goldshtein, H; Muhire, A; Petel Légaré, V; Peterson, RT; Pushett, A; Rotkopf, R; Russek-Blum, N; Shefner, JM, 2020) |
| "Rhabdomyolysis is one of the serious side effects of ciprofloxacin (CPFX), a widely used antibacterial drug; and occasionally, acute kidney injury (AKI) occurs." | 7.88 | Establishment of a drug-induced rhabdomyolysis mouse model by co-administration of ciprofloxacin and atorvastatin. ( Akai, S; Matsubara, A; Oda, S; Tsuneyama, K; Yokoi, T, 2018) |
| "Ciprofloxacin increases susceptibility to aortic dissection and rupture in a mouse model of moderate, sporadic AAD." | 7.88 | Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice. ( Azares, AR; Coselli, JS; LeMaire, SA; Luo, W; Ren, P; Shen, YH; Wang, Y; Zhang, C; Zhang, L, 2018) |
| "Korean red ginseng (KRG) may be a beneficial adjuvant along with ciprofloxacin to ameliorate devastating effects of epididymo-orchitis (EO) on male fertility." | 7.85 | Co-administration of ginseng and ciprofloxacin ameliorates epididymo-orchitis induced alterations in sperm quality and spermatogenic cells apoptosis following infection in rats. ( Eskandari, M; Eyni, H; Ghalyanchi Langeroudi, A; Kazemi, M; Rostami, A; Shokri, S; Zeighami, H, 2017) |
| "The study investigated the in vitro, ex vivo and in vivo efficacy of ajoene and ciprofloxacin (CIP) alone and in combination against Pseudomonas aeruginosa biofilms and biofilm-associated murine acute pyelonephritis." | 7.83 | Exploiting the antivirulence efficacy of an ajoene-ciprofloxacin combination against Pseudomonas aeruginosa biofilm associated murine acute pyelonephritis. ( Chhibber, S; Harjai, K; Saini, H; Vadekeetil, A, 2016) |
| "OTO-201 can provide sustained release to the middle ear and effectively treat otitis media, when compared with FDA-approved ciprofloxacin otic drop formulations." | 7.80 | OTO-201: nonclinical assessment of a sustained-release ciprofloxacin hydrogel for the treatment of otitis media. ( Altschuler, RA; Dellamary, L; Dolan, DF; Fernandez, R; Harrop-Jones, A; Hou, HJ; LeBel, C; Piu, F; Tsivkovskaia, N; Wang, X, 2014) |
| " Our objective is to evaluate the effectiveness of ciprofloxacin in the prevention of myringosclerosis that is created by myringotomy in rats and to compare it with prednisolone." | 7.78 | Evaluation of the effectiveness of topical ciprofloxacin and prednisolone in the prevention of myringosclerosis. ( Arslan, N; Caydere, M; Demirci, M; Oguz, H; Taştan, E; Tepe, D; Ustun, H, 2012) |
| " The current standard of care for inhalational anthrax postexposure prophylaxis is ciprofloxacin therapy twice daily for 60 days." | 7.74 | Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax. ( Arhin, FF; Bassett, A; Bassett, J; Heine, HS; Ivins, BE; Lehoux, D; Miller, L; Moeck, G; Parr, TR, 2008) |
| "The aim of this study was to evaluate the efficiency of methylene blue (MB) in preventing renal scar formation after the induction of pyelonephritis (PNP) in a rat model with delayed antimicrobial therapy." | 7.74 | The effects of methylene blue on renal scarring due to pyelonephritis in rats. ( Aksu, B; Aydin, S; Ayvaz, S; Durmus-Altun, G; Gurcan, S; Inan, M; Kanter, M; Oz Puyan, F; Pul, M; Uzun, H, 2007) |
| "We investigated the effects of epididymo-orchitis and ciprofloxacin on rat testicular histology and spermatogenesis." | 7.74 | Effect of experimentally induced Escherichia coli epididymo-orchitis and ciprofloxacin treatment on rat spermatogenesis. ( Demir, A; Findik, A; Onol, FF; Sirvanci, S; Tarcan, T; Türker, P, 2007) |
| " aureus keratitis, following the treatments, the median number of CFU of recoverable bacteria for chlorhexidine (n = 10), ciprofloxacin (n = 12), tobramycin/cefazolin (n = 12), and controls (n = 10) was 1." | 7.74 | A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis. ( Bouchard, CS; Bu, P; Carey, R; Riske, PS; Zaya, NE, 2007) |
| "Ciprofloxacin (CFX) implants containing poly(D,L-lactide) and calcium phosphates (tricalcium phosphate and hydroxyapatite) was evaluated in 50 rabbits in an experimental osteomyelitis model." | 7.74 | Efficacy of ciprofloxacin implants in treating experimental osteomyelitis. ( Alvarez, H; Castro, C; Delgado, A; Evora, C; Moujir, L; Perera, A; Sánchez, E; Soriano, I, 2008) |
| "A biodegradable system of poly-D,L-dilactide releasing ciprofloxacin was assessed in a Pseudomonas aeruginosa osteomyelitis model after inoculation of the test pathogen into the left tibia of 76 New Zealand White rabbits; 31 were controls (group A), and 45 were implanted with the polymer at the infection site (group B)." | 7.74 | Local treatment of experimental Pseudomonas aeruginosa osteomyelitis with a biodegradable dilactide polymer releasing ciprofloxacin. ( Andreopoulos, A; Dontas, I; Dounis, E; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kanellakopoulou, K; Karagiannakos, P; Kolia, M; Nakopoulou, L; Thivaios, GC, 2008) |
| "A dose-decreasing immunocompetent sepsis mouse model was used to evaluate the in vivo effect of levofloxacin, moxifloxacin and gemifloxacin, using a ciprofloxacin/levofloxacin susceptible serotype 6B strain (ciprofloxacin MIC: 1 mg/l) and two resistant serotype 14 and 19F strains with gyrA and parC point mutations (ciprofloxacin MICs of 32 and 64 mg/l, respectively)." | 7.73 | In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. ( Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D, 2005) |
| "3% is at least as effective as ciprofloxacin at healing corneal ulcers infected with Pseudomonas aeruginosa when gatifloxacin is administered less frequently than ciprofloxacin." | 7.73 | Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. ( Carrier, M; Jensen, H; Short, B; Zerouala, C, 2005) |
| "Taurolidine is a broad-spectrum, non antibiotic antimicrobial agent, not previously tested against the common causes of bacterial keratitis." | 7.73 | Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model. ( Gurkan, T; Oguz, E; Oguz, H; Ozbilge, H, 2005) |
| "The effect of liposome delivery on the controlled release and therapeutic efficacy of ciprofloxacin against intracellular Francisella tularensis infection in vivo was evaluated in this study." | 7.72 | Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. ( Blasetti, KL; Conley, J; Schnell, G; Schofield, LN; Wong, JP; Yang, H, 2003) |
| "This study was designed to compare the killing effect of ciprofloxacin on strains of Klebsiella pneumoniae with different MICs of ciprofloxacin in vivo using the rat granuloma pouch infection model." | 7.71 | Significance of low-level resistance to ciprofloxacin in Klebsiella pneumoniae and the effect of increased dosage of ciprofloxacin in vivo using the rat granuloma pouch model. ( Fuursted, K; Schumacher, H, 2002) |
| "A deep-seated Pseudomonas aeruginosa mouse kidney abscess model was used to compare the therapeutic efficacy of clinafloxacin, a fluoroquinolone in clinical trials, with that of clinically relevant standard drugs." | 7.70 | Comparative therapeutic efficacy of clinafloxacin in a Pseudomonas aeruginosa mouse renal abscess model. ( Desaty, TM; Griffin, TJ; Heifetz, CL; Sesnie, JC; Shapiro, MA, 1998) |
| " This study, employing an experimental rabbit model of Staphylococcus keratitis, compared the effectiveness of two commonly prescribed formulations of fluoroquinolones to an experimental formulation, ciprofloxacin with polystyrene sulfonate (ciprofloxacin-PSS)." | 7.70 | Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model. ( Engel, LS; Green, LC; Hill, JM; Moreau, JM; O'Callaghan, RJ, 1998) |
| "To determine injection time and effective dose of ciprofloxacin in endophthalmitis and to evaluate the effectiveness of dexamethasone." | 7.69 | Efficacy of ciprofloxacin and dexamethasone in experimental pseudomonas endophthalmitis. ( Chung, KH; Kim, IT; Koo, BS, 1996) |
| "The authors compare the intravitreal efficacy of ciprofloxacin, vancomycin and imipenem, in treating experimental Bacillus cereus endophthalmitis." | 7.69 | Experimental posttraumatic Bacillus cereus endophthalmitis in a swine model. Efficacy of intravitreal ciprofloxacin, vancomycin, and imipenem. ( Alfaro, DV; Bevin, AA; Hudson, SJ; Laughlin, RM; Mines, M; offele, JJ; Schoderbek, RJ, 1996) |
| "36% tobramycin in two experimental models of keratitis, using a methicillin-sensitive strain of Staphylococcus aureus and an aminoglycoside-sensitive strain of Pseudomonas aeruginosa, respectively." | 7.68 | Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis. ( Cohen, KL; Lauffenburger, MD, 1993) |
| "An experimental Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats was used to study the impact of the duration of infection on the bactericidal activity of ceftazidime, gentamicin and ciprofloxacin." | 7.68 | Impact of the duration of infection on the activity of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1991) |
| "After induction of experimental polymicrobic osteomyelitis with Staphylococcus epidermidis and Bacteroides thetaiotaomicron (ciprofloxacin MIC, 0." | 7.68 | Effect of ciprofloxacin on experimental osteomyelitis in the rabbit tibia, induced with a mixed infection of Staphylococcus epidermidis and Bacteroides thetaiotaomicron. ( Gill, LR; Hossler, FE; Lambe, DW; Mayberry-Carson, KJ; Tober-Meyer, B, 1990) |
| "The efficacies of the quinolones ciprofloxacin and pefloxacin alone and in combination with rifampin were compared with those of vancomycin alone and in combination with rifampin in a rat model of chronic osteomyelitis caused by methicillin-resistant Staphylococcus aureus." | 7.68 | Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. ( Dworkin, R; Kunz, S; Modin, G; Rich, R; Sande, M; Zak, O, 1990) |
| "The penetration, pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin were investigated in a rat abscess model." | 7.67 | The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ( Barzilai, A; Keren, G; Leibovitz, E; Rubinstein, E; Shabtai, M, 1989) |
| "The potential of ciprofloxacin for the therapy of Pseudomonas aeruginosa meningitis was evaluated in an animal model by determining the penetration of the drug into CSF, its concentration-dependent killing characteristics in vivo, and its relative efficacy compared with ceftazidime and tobramycin." | 7.67 | Ciprofloxacin in experimental Pseudomonas aeruginosa meningitis in rabbits. ( Chambers, HF; Hackbarth, CJ; Sande, MA; Shibl, AM; Stella, F, 1986) |
| "Staphylococcus aureus induced brain abscess is a critical health concern throughout the developing world." | 5.62 | Ciprofloxacin and dexamethasone in combination attenuate S. aureus induced brain abscess via neuroendocrine-immune interaction of TLR-2 and glucocorticoid receptor leading to behavioral improvement. ( Bishayi, B; Dey, R, 2021) |
| " Many antibiotics at appropriate concentrations improved the survival rate and alleviated tissue injury, while, when dosing strategies fall below subtherapeutic levels, worse therapeutic effects are seen." | 5.46 | Low-dose norfloxacin and ciprofloxacin therapy worsen leptospirosis in hamster. ( Cao, Y; Guo, J; Jin, X; Lin, T; Wang, T; Wu, D; Wu, R; Xie, X; Zhang, W, 2017) |
| "Telavancin displays potent in vitro and in vivo activity against methicillin-resistant Staphylococcus aureus (MRSA), including strains with reduced susceptibility to vancomycin." | 5.36 | Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. ( Crandon, JL; Kuti, JL; Nicolau, DP, 2010) |
| " However, the treatment outcome is not ideal and long-term administration of antibiotics can result in adverse effects and bacterial resistance." | 5.35 | Synergistic effect between lycopene and ciprofloxacin on a chronic bacterial prostatitis rat model. ( Cho, YH; Han, CH; Kang, SH; Kim, SW; Sohn, DW; Yang, CH, 2008) |
| "Both ciprofloxacin treated groups improved radiographically from week 4 to week 10." | 5.32 | Prevention and treatment of experimental osteomyelitis in dogs with ciprofloxacin-loaded crosslinked high amylose starch implants. ( Chouinard, L; Désévaux, C; Dubreuil, P; Huneault, LM; Lussier, B, 2004) |
| " In the survival study, a dose-response effect of ciprofloxacin on survival was observed (ciprofloxacin: 10 mg/kg, 10%; 50 mg/kg, 26%; and 100 mg/kg, 35%) with the results in the 100-mg/kg-treated group being significant when compared with the 5% survival rate in saline-treated controls (P < ." | 5.30 | The beneficial effects of ciprofloxacin on survival and hepatic regenerative activity in a rat model of fulminant hepatic failure. ( Assy, N; Gauthier, T; Kaita, KD; Meyers, AF; Minuk, GY; Zhang, M, 1998) |
| "Ciprofloxacin is a fluoroquinolone antibiotic with broad spectrum bactericidal activity." | 5.29 | The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis. ( Callegan, MC; Engel, LS; Folkens, AT; Hill, JM; O'Callaghan, RJ; Shimomura, Y, 1996) |
| "Ciprofloxacin has been studied extensively in discriminative animal models of infection, and its efficacy in the treatment of these infections has been compared with that of standard therapy." | 5.27 | Efficacy of ciprofloxacin in animal models of infection: endocarditis, meningitis, and pneumonia. ( Brooks-Fournier, RA; Gerberding, JL; Sande, MA, 1987) |
| "In August 2000, the US Food and Drug Administration (FDA) approved ciprofloxacin hydrochloride (Cipro; Bayer) for management of postexposure inhalational anthrax." | 4.82 | US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax. ( Albrecht, R; Dionne, P; Higgins, K; Meyer, JM; Meyerhoff, A; Murphy, D, 2004) |
| "In the clindamycin group, 8 of 11 (73%) survived demonstrating its efficacy for the first time in inhalational anthrax, compared to 9 of 9 (100%) with ciprofloxacin, and 8 of 11 (73%) with ciprofloxacin + clindamycin." | 4.02 | Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin. ( Barr, JR; Boyer, AE; Chabot, DJ; Cote, CK; Fetterer, DP; Friedlander, AM; Ingavale, S; Klimko, CP; Miller, JA; Schellhase, CW; Somerville, BC; Tobery, SA; Twenhafel, NA; Vietri, NJ; Woolfitt, AR; Wright, ME, 2021) |
| "The in vivo efficacy of liposomal encapsulated ciprofloxacin in two formulations, lipoquin and apulmiq, were evaluated against the causative agent of anthrax, Bacillus anthracis." | 3.96 | Evaluation of liposomal ciprofloxacin formulations in a murine model of anthrax. ( Blanchard, JD; Crichton, M; Jager, S; Stratilo, CW, 2020) |
| "Ciprofloxacin and levofloxacin, 2 fluoroquinolone antimicrobials, are ≥90% effective for the treatment of inhalational plague when administered within 2-6 hours of fever onset in African green monkeys (AGM)." | 3.96 | Effect of Delaying Treatment on Efficacy of Ciprofloxacin and Levofloxacin in the African Green Monkey Model of Pneumonic Plague. ( Campbell, JL; Fay, MP; Hewitt, JA; Lanning, LL, 2020) |
| "To evaluate the efficacy of a fixed-dose combination of two approved drugs, Ciprofloxacin and Celecoxib, as a potential therapeutic treatment for amyotrophic lateral sclerosis (ALS)." | 3.96 | Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis. ( Armstrong, GAB; Goldshtein, H; Muhire, A; Petel Légaré, V; Peterson, RT; Pushett, A; Rotkopf, R; Russek-Blum, N; Shefner, JM, 2020) |
| "The purpose of this work was to develop an effective carbomer hydrogel to be used to treat second-degree burns that combined ciprofloxacin and lidocaine (CbCipLid hydrogel)." | 3.88 | Ciprofloxacin-lidocaine-based hydrogel: development, characterization, and in vivo evaluation in a second-degree burn model. ( Breda, SA; Manzo, RH; Olivera, ME; Sanchez, MF; Soria, EA; Tártara, LI, 2018) |
| "Rhabdomyolysis is one of the serious side effects of ciprofloxacin (CPFX), a widely used antibacterial drug; and occasionally, acute kidney injury (AKI) occurs." | 3.88 | Establishment of a drug-induced rhabdomyolysis mouse model by co-administration of ciprofloxacin and atorvastatin. ( Akai, S; Matsubara, A; Oda, S; Tsuneyama, K; Yokoi, T, 2018) |
| "Ciprofloxacin increases susceptibility to aortic dissection and rupture in a mouse model of moderate, sporadic AAD." | 3.88 | Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice. ( Azares, AR; Coselli, JS; LeMaire, SA; Luo, W; Ren, P; Shen, YH; Wang, Y; Zhang, C; Zhang, L, 2018) |
| "Korean red ginseng (KRG) may be a beneficial adjuvant along with ciprofloxacin to ameliorate devastating effects of epididymo-orchitis (EO) on male fertility." | 3.85 | Co-administration of ginseng and ciprofloxacin ameliorates epididymo-orchitis induced alterations in sperm quality and spermatogenic cells apoptosis following infection in rats. ( Eskandari, M; Eyni, H; Ghalyanchi Langeroudi, A; Kazemi, M; Rostami, A; Shokri, S; Zeighami, H, 2017) |
| "The study investigated the in vitro, ex vivo and in vivo efficacy of ajoene and ciprofloxacin (CIP) alone and in combination against Pseudomonas aeruginosa biofilms and biofilm-associated murine acute pyelonephritis." | 3.83 | Exploiting the antivirulence efficacy of an ajoene-ciprofloxacin combination against Pseudomonas aeruginosa biofilm associated murine acute pyelonephritis. ( Chhibber, S; Harjai, K; Saini, H; Vadekeetil, A, 2016) |
| "OTO-201 can provide sustained release to the middle ear and effectively treat otitis media, when compared with FDA-approved ciprofloxacin otic drop formulations." | 3.80 | OTO-201: nonclinical assessment of a sustained-release ciprofloxacin hydrogel for the treatment of otitis media. ( Altschuler, RA; Dellamary, L; Dolan, DF; Fernandez, R; Harrop-Jones, A; Hou, HJ; LeBel, C; Piu, F; Tsivkovskaia, N; Wang, X, 2014) |
| "The purpose of this study was to evaluate ciprofloxacin-releasing silicone hydrogel contact lens materials in vitro and in vivo for the treatment of microbial keratitis." | 3.80 | In vitro and in vivo evaluation of novel ciprofloxacin-releasing silicone hydrogel contact lenses. ( Hui, A; Jones, L; Willcox, M, 2014) |
| "The increasing spread of chloroquine resistant malaria has intensified the search for new antimalarial treatment, especially drugs that can be used in combination." | 3.78 | Interaction between ciprofloxacin and chloroquine in mice infected with chloroquine resistant Plasmodium berghei: interaction between ciprofloxacin and chloroqune. ( Abiodun, OO; Gbotosho, GO; Happi, CT; Oduola, AM; Sowunmi, A; Woranola, O, 2012) |
| " Our objective is to evaluate the effectiveness of ciprofloxacin in the prevention of myringosclerosis that is created by myringotomy in rats and to compare it with prednisolone." | 3.78 | Evaluation of the effectiveness of topical ciprofloxacin and prednisolone in the prevention of myringosclerosis. ( Arslan, N; Caydere, M; Demirci, M; Oguz, H; Taştan, E; Tepe, D; Ustun, H, 2012) |
| "For 3 weeks, we administered oral AB (ciprofloxacin/metronidazole) or control treatment to homozygous ΔF508 (Δ/Δ), cystic fibrosis transmembrane conductance regulator (CFTR) knockout (-/-), and wild-type (WT) mice and quantified fat absorption using a 72-h fat balance test." | 3.78 | Effect of antibiotic treatment on fat absorption in mice with cystic fibrosis. ( Bijvelds, MJ; Burgerhof, JG; de Jonge, HR; De Lisle, RC; Verkade, HJ; Wouthuyzen-Bakker, M, 2012) |
| "In cirrhotic rats, ciprofloxacin suppressed endotoxemia and the hepatic endocannabinoid system thus ameliorating hyperdynamic circulation and decreased intrahepatic resistance by preventing hepatic fibrogenesis and endothelial dysfunction." | 3.77 | The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension. ( Huang, CM; Huang, YT; Lee, FY; Lee, SD; Lin, HC; Liu, TT; Tsai, TH; Yang, YY, 2011) |
| "This study demonstrated that treatment with a combination of topical ciprofloxacin and corticosteroid decreased the middle ear effusion when compared with the control group and that ciprofloxacin/dexamethasone suspension reduced the severity of LPS-induced experimental otitis media more than ciprofloxacin/hydrocortisone did." | 3.77 | Effect of ciprofloxacin/dexamethasone versus ciprofloxacin/hydrocortisone on lipopolysaccharide-induced experimental otitis media. ( Chung, YS; Dattaray, P; Jahng, P; Jung, T; Kim, YH; Martin, D; Nyc, MA; Pudrith, C; Wall, GM, 2011) |
| "The aim of this study was to compare the pharmacokinetics and efficacy of ciprofloxacin as post-exposure therapy against inhalational anthrax in the common marmoset (Callithrix jacchus) with other non-human primate models in order to determine whether the marmoset is a suitable model to test post-exposure therapies for anthrax." | 3.77 | Post-exposure therapy of inhalational anthrax in the common marmoset. ( Brown, MA; Lever, MS; Nelson, M; Pearce, PC; Simpson, AJ; Stagg, AJ; Stevens, DJ, 2011) |
| "To compare the therapeutic effectiveness of a single intrastromal dose of gentamycin, tobramycin, ciprofloxacin and ofloxacin for the treatment of corneal ulcers due to Pseudomonas aeruginosa." | 3.75 | [Bacterial corneal ulcer treated with intrastromal antibiotic. Experimental model in vivo]. ( Naranjo-Tackman, R; Stangogiannis-Druya, C; Stangogiannis-Druya, E; Vanzzini, V; Villar-Kurí, J, 2009) |
| " The current standard of care for inhalational anthrax postexposure prophylaxis is ciprofloxacin therapy twice daily for 60 days." | 3.74 | Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax. ( Arhin, FF; Bassett, A; Bassett, J; Heine, HS; Ivins, BE; Lehoux, D; Miller, L; Moeck, G; Parr, TR, 2008) |
| "The aim of this study was to evaluate the efficiency of methylene blue (MB) in preventing renal scar formation after the induction of pyelonephritis (PNP) in a rat model with delayed antimicrobial therapy." | 3.74 | The effects of methylene blue on renal scarring due to pyelonephritis in rats. ( Aksu, B; Aydin, S; Ayvaz, S; Durmus-Altun, G; Gurcan, S; Inan, M; Kanter, M; Oz Puyan, F; Pul, M; Uzun, H, 2007) |
| "We investigated the effects of epididymo-orchitis and ciprofloxacin on rat testicular histology and spermatogenesis." | 3.74 | Effect of experimentally induced Escherichia coli epididymo-orchitis and ciprofloxacin treatment on rat spermatogenesis. ( Demir, A; Findik, A; Onol, FF; Sirvanci, S; Tarcan, T; Türker, P, 2007) |
| " aureus keratitis, following the treatments, the median number of CFU of recoverable bacteria for chlorhexidine (n = 10), ciprofloxacin (n = 12), tobramycin/cefazolin (n = 12), and controls (n = 10) was 1." | 3.74 | A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis. ( Bouchard, CS; Bu, P; Carey, R; Riske, PS; Zaya, NE, 2007) |
| "Ciprofloxacin (CFX) implants containing poly(D,L-lactide) and calcium phosphates (tricalcium phosphate and hydroxyapatite) was evaluated in 50 rabbits in an experimental osteomyelitis model." | 3.74 | Efficacy of ciprofloxacin implants in treating experimental osteomyelitis. ( Alvarez, H; Castro, C; Delgado, A; Evora, C; Moujir, L; Perera, A; Sánchez, E; Soriano, I, 2008) |
| "A biodegradable system of poly-D,L-dilactide releasing ciprofloxacin was assessed in a Pseudomonas aeruginosa osteomyelitis model after inoculation of the test pathogen into the left tibia of 76 New Zealand White rabbits; 31 were controls (group A), and 45 were implanted with the polymer at the infection site (group B)." | 3.74 | Local treatment of experimental Pseudomonas aeruginosa osteomyelitis with a biodegradable dilactide polymer releasing ciprofloxacin. ( Andreopoulos, A; Dontas, I; Dounis, E; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kanellakopoulou, K; Karagiannakos, P; Kolia, M; Nakopoulou, L; Thivaios, GC, 2008) |
| "A dose-decreasing immunocompetent sepsis mouse model was used to evaluate the in vivo effect of levofloxacin, moxifloxacin and gemifloxacin, using a ciprofloxacin/levofloxacin susceptible serotype 6B strain (ciprofloxacin MIC: 1 mg/l) and two resistant serotype 14 and 19F strains with gyrA and parC point mutations (ciprofloxacin MICs of 32 and 64 mg/l, respectively)." | 3.73 | In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. ( Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D, 2005) |
| "3% is at least as effective as ciprofloxacin at healing corneal ulcers infected with Pseudomonas aeruginosa when gatifloxacin is administered less frequently than ciprofloxacin." | 3.73 | Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. ( Carrier, M; Jensen, H; Short, B; Zerouala, C, 2005) |
| "Taurolidine is a broad-spectrum, non antibiotic antimicrobial agent, not previously tested against the common causes of bacterial keratitis." | 3.73 | Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model. ( Gurkan, T; Oguz, E; Oguz, H; Ozbilge, H, 2005) |
| "The fourth-generation fluoroquinolone, gatifloxacin, is an effective prophylaxis against the development of keratitis after lamellar keratectomy in rabbits with an organism resistant to methicillin, levofloxacin, and ciprofloxacin." | 3.72 | Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model. ( Carpenter, TR; Kaufman, MB; McDonnell, PJ; Sarayba, MA; Sweet, PM; Taban, M; Tungsiripat, T, 2003) |
| "The effect of liposome delivery on the controlled release and therapeutic efficacy of ciprofloxacin against intracellular Francisella tularensis infection in vivo was evaluated in this study." | 3.72 | Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. ( Blasetti, KL; Conley, J; Schnell, G; Schofield, LN; Wong, JP; Yang, H, 2003) |
| "The efficacies of prophylactic and therapeutic gatifloxacin and moxifloxacin were assessed in a BALB/c mouse model of systemic and pneumonic plague and compared with ciprofloxacin." | 3.72 | Efficacy of the latest fluoroquinolones against experimental Yersinia pestis. ( Beedham, RJ; Brooks, TJ; Lever, MS; Russell, P; Stagg, AJ; Steward, J; Taylor, RR, 2004) |
| "This study was designed to compare the killing effect of ciprofloxacin on strains of Klebsiella pneumoniae with different MICs of ciprofloxacin in vivo using the rat granuloma pouch infection model." | 3.71 | Significance of low-level resistance to ciprofloxacin in Klebsiella pneumoniae and the effect of increased dosage of ciprofloxacin in vivo using the rat granuloma pouch model. ( Fuursted, K; Schumacher, H, 2002) |
| "The efficacies of ciprofloxacin and doxycycline prophylaxis and therapy were assessed against experimental pneumonic plague infections induced by two strains of Yersinia pestis in a mouse model." | 3.70 | Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection. ( Beedham, RJ; Bell, DL; Eley, SM; Green, M; Nelson, M; Rogers, D; Russell, P; Stagg, AJ; Taylor, RR; Titball, RW; Whittington, D, 1998) |
| "A deep-seated Pseudomonas aeruginosa mouse kidney abscess model was used to compare the therapeutic efficacy of clinafloxacin, a fluoroquinolone in clinical trials, with that of clinically relevant standard drugs." | 3.70 | Comparative therapeutic efficacy of clinafloxacin in a Pseudomonas aeruginosa mouse renal abscess model. ( Desaty, TM; Griffin, TJ; Heifetz, CL; Sesnie, JC; Shapiro, MA, 1998) |
| " This study, employing an experimental rabbit model of Staphylococcus keratitis, compared the effectiveness of two commonly prescribed formulations of fluoroquinolones to an experimental formulation, ciprofloxacin with polystyrene sulfonate (ciprofloxacin-PSS)." | 3.70 | Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model. ( Engel, LS; Green, LC; Hill, JM; Moreau, JM; O'Callaghan, RJ, 1998) |
| " The purpose of this investigation was to develop and characterize a biodegradable, implantable delivery system containing ciprofloxacin hydrochloride (HCl) for the localized treatment of osteomyelitis and to study the extent of drug penetration from the site of implantation into the bone." | 3.70 | In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants. ( Ramchandani, M; Robinson, D, 1998) |
| "Ciprofloxacin and prednisolone, but not an aminoglycoside and dexamethasone, were previously found to be effective in killing bacteria and reducing inflammation for the treatment of Pseudomonas keratitis." | 3.69 | Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. ( Callegan, MC; Engel, LS; Hill, JM; Hobden, JA; O'Callaghan, RJ; Reidy, JJ, 1995) |
| "Comparative antibacterial activity and protective efficacy of ciprofloxacin, pefloxacin and lomefloxacin were estimated in a model of anthrax." | 3.69 | [Comparative evaluation of the effectiveness of fluoroquinolones in experimental anthrax infection]. ( D'iakov, SI; Katsalukha, VV; Lebedeva, IK; Lukashina, AV; Raĭskaia, VA, 1994) |
| "To determine injection time and effective dose of ciprofloxacin in endophthalmitis and to evaluate the effectiveness of dexamethasone." | 3.69 | Efficacy of ciprofloxacin and dexamethasone in experimental pseudomonas endophthalmitis. ( Chung, KH; Kim, IT; Koo, BS, 1996) |
| "The authors compare the intravitreal efficacy of ciprofloxacin, vancomycin and imipenem, in treating experimental Bacillus cereus endophthalmitis." | 3.69 | Experimental posttraumatic Bacillus cereus endophthalmitis in a swine model. Efficacy of intravitreal ciprofloxacin, vancomycin, and imipenem. ( Alfaro, DV; Bevin, AA; Hudson, SJ; Laughlin, RM; Mines, M; offele, JJ; Schoderbek, RJ, 1996) |
| "36% tobramycin in two experimental models of keratitis, using a methicillin-sensitive strain of Staphylococcus aureus and an aminoglycoside-sensitive strain of Pseudomonas aeruginosa, respectively." | 3.68 | Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis. ( Cohen, KL; Lauffenburger, MD, 1993) |
| "A rabbit model of Staphylococcus aureus keratitis was developed to study the chemotherapeutic efficacy of ciprofloxacin, vancomycin, and cefazolin." | 3.68 | Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. ( Callegan, MC; Hill, JM; Hobden, JA; Insler, MS; O'Callaghan, RJ, 1992) |
| "An experimental Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats was used to study the impact of the duration of infection on the bactericidal activity of ceftazidime, gentamicin and ciprofloxacin." | 3.68 | Impact of the duration of infection on the activity of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1991) |
| "After induction of experimental polymicrobic osteomyelitis with Staphylococcus epidermidis and Bacteroides thetaiotaomicron (ciprofloxacin MIC, 0." | 3.68 | Effect of ciprofloxacin on experimental osteomyelitis in the rabbit tibia, induced with a mixed infection of Staphylococcus epidermidis and Bacteroides thetaiotaomicron. ( Gill, LR; Hossler, FE; Lambe, DW; Mayberry-Carson, KJ; Tober-Meyer, B, 1990) |
| "The efficacies of the quinolones ciprofloxacin and pefloxacin alone and in combination with rifampin were compared with those of vancomycin alone and in combination with rifampin in a rat model of chronic osteomyelitis caused by methicillin-resistant Staphylococcus aureus." | 3.68 | Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. ( Dworkin, R; Kunz, S; Modin, G; Rich, R; Sande, M; Zak, O, 1990) |
| "The penetration, pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin were investigated in a rat abscess model." | 3.67 | The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model. ( Barzilai, A; Keren, G; Leibovitz, E; Rubinstein, E; Shabtai, M, 1989) |
| "Five antimicrobial drugs (ciprofloxacin, clindamycin, imipenem, penicillin G, and rifampin) were examined for therapeutic efficacy in a murine model gas gangrene due to Clostridium perfringens type A, following infection with large bacterial inocula." | 3.67 | Chemotherapy of experimental (murine) Clostridium perfringens type A gas gangrene. ( Traub, WH, 1988) |
| "The potential of ciprofloxacin for the therapy of Pseudomonas aeruginosa meningitis was evaluated in an animal model by determining the penetration of the drug into CSF, its concentration-dependent killing characteristics in vivo, and its relative efficacy compared with ceftazidime and tobramycin." | 3.67 | Ciprofloxacin in experimental Pseudomonas aeruginosa meningitis in rabbits. ( Chambers, HF; Hackbarth, CJ; Sande, MA; Shibl, AM; Stella, F, 1986) |
| "Ciprofloxacin has been extensively investigated in various animal models of infection." | 2.37 | Animal models: the in-vivo evaluation of ciprofloxacin. ( Peterson, LR, 1986) |
| "Bacteremia-induced sepsis is a leading cause of mortality in intensive care units." | 1.62 | Multifunctional lipid-based nanocarriers with antibacterial and anti-inflammatory activities for treating MRSA bacteremia in mice. ( Alalaiwe, A; Dai, YS; Fang, JY; Liao, CC; Liu, FC; Yang, SC; Yu, HP, 2021) |
| "Staphylococcus aureus induced brain abscess is a critical health concern throughout the developing world." | 1.62 | Ciprofloxacin and dexamethasone in combination attenuate S. aureus induced brain abscess via neuroendocrine-immune interaction of TLR-2 and glucocorticoid receptor leading to behavioral improvement. ( Bishayi, B; Dey, R, 2021) |
| " Initial development of a PEP model for inhalational anthrax included evaluation of post-exposure ciprofloxacin pharmacokinetics (PK), tolerability and survival in guinea pigs treated with various ciprofloxacin dosing regimens." | 1.56 | Development of a guinea pig inhalational anthrax model for evaluation of post-exposure prophylaxis efficacy of anthrax vaccines. ( Barnewall, RE; Ionin, B; Lemiale, L; Park, S; Perry, MR; Reece, JJ; Savransky, V; Shearer, JD; Skiadopoulos, MH; Vassar, ML, 2020) |
| " Previously, we demonstrated that the complexation of CIP with copper (CIP-Cu) reduces its apparent epithelial permeability and pulmonary absorption rate without affecting antimicrobial activity against Pseudomonas aeruginosa grown planktonically or as biofilms." | 1.56 | In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa. ( Bahamondez-Canas, TF; Moraga-Espinoza, D; Smyth, HDC; Tewes, F; Watts, AB, 2020) |
| " A microdialysis (MD) combined with liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated to determine free gemifloxacin concentrations in rat plasma and skeletal muscle simultaneously." | 1.51 | Microdialysis combined with liquid chromatography-tandem mass spectrometry for the quantitation of gemifloxacin and its application to a muscle penetration study in healthy and MRSA-infected rats. ( Hu, XX; Jiang, JD; Li, CR; Lu, X; Nie, TY; Pang, J; Wang, Q; Wang, X; Yang, XY; You, XF; Zhao, R, 2019) |
| "In a mouse skin wound infection model, F6 was equipotent to the antibiotic fusidic acid in reducing MRSA burden." | 1.48 | N-(1,3,4-oxadiazol-2-yl)benzamide analogs, bacteriostatic agents against methicillin- and vancomycin-resistant bacteria. ( Abutaleb, NS; Dayal, N; Mohammad, H; Naclerio, GA; Opoku-Temeng, C; Seleem, MN; Sintim, HO, 2018) |
| "Treatment of anthrax is challenging, especially during the advanced stages of the disease." | 1.48 | Treating Anthrax-Induced Meningitis in Rabbits. ( Bar-David, E; Ben-Shmuel, A; Brosh, T; Glinert, I; Kobiler, D; Levy, H; Schlomovitz, J; Sittner, A; Weiss, S, 2018) |
| "Sepsis is a life-threatening disease resulted from a dysregulated host immune response to bacterial infections, continuing to cause high morbidity and mortality worldwide." | 1.48 | Bioresponsive Nanoparticles Targeted to Infectious Microenvironments for Sepsis Management. ( Gao, J; Wang, Z; Zhang, CY, 2018) |
| " Many antibiotics at appropriate concentrations improved the survival rate and alleviated tissue injury, while, when dosing strategies fall below subtherapeutic levels, worse therapeutic effects are seen." | 1.46 | Low-dose norfloxacin and ciprofloxacin therapy worsen leptospirosis in hamster. ( Cao, Y; Guo, J; Jin, X; Lin, T; Wang, T; Wu, D; Wu, R; Xie, X; Zhang, W, 2017) |
| "Ciprofloxacin is a common, broad spectrum antibacterial agent; however, evidence is accumulating that ciprofloxacin may cause liver damage." | 1.43 | Quercetin protection against ciprofloxacin induced liver damage in rats. ( Cetin, A; Dogan, Z; Elbe, H; Taslidere, E; Turkoz, Y; Vardi, N, 2016) |
| "The aac(6')-Ib-cr gene, in spite of producing low-level resistance by itself, plays a relevant role in acquisition of a clinical level of ciprofloxacin and norfloxacin resistance, when combined with three or four chromosomal mutations, both in vitro and in vivo." | 1.43 | Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli. ( Díaz-De-Alba, P; Docobo-Perez, F; Machuca, J; Ortiz, M; Pascual, Á; Recacha, E; Rodríguez-Martínez, JM, 2016) |
| "aeruginosa murine burn wound infection." | 1.42 | Efficacy of purified lactonase and ciprofloxacin in preventing systemic spread of Pseudomonas aeruginosa in murine burn wound model. ( Chhibber, S; Gupta, P; Harjai, K, 2015) |
| "Clarithromycin and rifampin were shown to be effective only as a postexposure prophylactic treatment but failed to treat the systemic (bacteremic) phase of anthrax." | 1.42 | Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits. ( Altboum, Z; Bar-David, E; Glinert, I; Kobiler, D; Levy, H; Schlomovitz, J; Sittner, A; Weiss, S, 2015) |
| " CD nanocapsules were successfully employed for efficient targeting and killing of the intracellular pathogen at a dosage significantly lower than that of the free antibiotic." | 1.39 | Chitosan-dextran sulphate nanocapsule drug delivery system as an effective therapeutic against intraphagosomal pathogen Salmonella. ( Ben Thomas, M; Chakravortty, D; Elango, M; Gnanadhas, DP; Raichur, AM, 2013) |
| " Vesicle formation observed from 48 hr after irradiation was considered similar to bullous eruptions, a known side effect of fluoroquinolones in humans." | 1.39 | A dermal phototoxicity study following intravenous infusion administration of ciprofloxacin hydrochloride in the novel microminipigs. ( Izumi, H; Kawaguchi, H; Miura, N; Miyoshi, N; Takahashi, Y; Tanimoto, A; Utsunomiya, S; Yoshikawa, T, 2013) |
| "Traditional first-line treatment of chronic bacterial prostatitis (CBP) is administration of empirical antibiotics." | 1.37 | Do Escherichia coli extract and cranberry exert preventive effects on chronic bacterial prostatitis? Pilot study using an animal model. ( Cho, YH; Ha, US; Han, CH; Kim, HW; Kim, SH; Lee, CB; Lee, HR; Lee, SJ; Sohn, DW, 2011) |
| " The rabbits received ciprofloxacin 10 times a day at a 2-hour dosing interval." | 1.37 | [Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ( Li, Y; Liu, MT; Sheng, MY; Zhang, Y, 2011) |
| " The sigmoid maximum-threshold-of-efficacy (E(max)) model fit the survival data, in which the free-drug area under the concentration-time curve (fAUC)/MIC ratio, the maximum concentration of free drug in plasma (fC(max))/MIC ratio, and the cumulative percentage of a 24-h period that the free-drug concentration exceeds the MIC under steady-state pharmacokinetic conditions (f %T(MIC)) were each evaluated." | 1.36 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. ( Ambrose, PG; Bassett, J; Beaudry, A; Bhavnani, SM; Critchley, I; Gill, SC; Heine, HS; Janjic, N; Li, J; Miller, L; Rubino, CM; Stone, KC, 2010) |
| "Telavancin displays potent in vitro and in vivo activity against methicillin-resistant Staphylococcus aureus (MRSA), including strains with reduced susceptibility to vancomycin." | 1.36 | Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. ( Crandon, JL; Kuti, JL; Nicolau, DP, 2010) |
| "Levofloxacin 1." | 1.36 | Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models. ( Gordon, YJ; Kowalski, RP; Mah, FS; Romanowski, EG; Shanks, RM, 2010) |
| "Osteomyelitis is a difficult to treat bacterial infection of the bone." | 1.35 | Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis. ( Arhin, FF; Caron, L; Delorme, D; Dietrich, E; Fadhil, I; Ferreira, SS; Houghton, TJ; Kang, T; Laquerre, K; Lehoux, D; Liu, J; Moeck, G; Ostiguy, V; Parr, TR; Poirier, H; Rafai Far, A; Sarmiento, I; Tanaka, KS; Viens, F, 2008) |
| "5%, wt/wt) showed optimum release and mucoadhesion properties and improved ocular bioavailability as evidenced by an enhanced therapeutic response compared with the marketed conventional eye drops." | 1.35 | Ocular poloxamer-based ciprofloxacin hydrochloride in situ forming gels. ( Abd Elhady, SS; Mansour, M; Mansour, S; Mortada, ND, 2008) |
| " However, the treatment outcome is not ideal and long-term administration of antibiotics can result in adverse effects and bacterial resistance." | 1.35 | Synergistic effect between lycopene and ciprofloxacin on a chronic bacterial prostatitis rat model. ( Cho, YH; Han, CH; Kang, SH; Kim, SW; Sohn, DW; Yang, CH, 2008) |
| "The clinical course in acute necrotizing pancreatitis is mainly determined by bacterial infection of pancreatic and peripancreatic necrosis." | 1.34 | Effect of early and late antibiotic treatment in experimental acute pancreatitis in rats. ( Beger, HG; Gansauge, F; Isenmann, R; Kriese, D; Poch, B; Rozdzinski, E; Schwarz, M, 2007) |
| "Bacterial wound infection is a major problem, which hinders the normal healing process." | 1.34 | Collagen bilayer dressing with ciprofloxacin, an effective system for infected wound healing. ( Ahmed, MR; Kumar, MS; Sehgal, PK; Sripriya, R, 2007) |
| "Ciprofloxacin was administered daily via drinking water at concentrations to provide doses of 0, 0." | 1.33 | Impact of residual and therapeutic doses of ciprofloxacin in the human-flora-associated mice model. ( Bartholomew, M; Corpet, DE; Fernández, AH; Perrin-Guyomard, A; Poul, JM; Sanders, P, 2005) |
| "Ciprofloxacin-treated animals had higher survival compared with clindamycin-treated animals in two experiments, and less survival in a third experiment, although differences were not statistically significant." | 1.33 | Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in 60Co-gamma-photon-irradiated and sham-irradiated mice. ( Bolduc, DL; Brook, I; Camp-Hyde, TD; Elliott, TB; Foriska, MA; Germana, A; Giraldo, DE; Jackson, WE; Ledney, GD; Shoemaker, MO; Thakar, JH, 2005) |
| " In an exploratory long-term in vivo study with three rabbits, ciprofloxacin could not be detected from the serum after moderate filling (160 mg) of the tibia (follow-up 168 days), whereas after high dosing (a total dose of 1,000 mg in both tibias) ciprofloxacin was found temporarily at low serum concentrations (14-34 ng/mL) during the follow-up of 300 days." | 1.33 | In vitro and in vivo testing of bioabsorbable antibiotic containing bone filler for osteomyelitis treatment. ( Aro, HT; Jalava, J; Koort, JK; Mäkinen, TJ; Suokas, E; Törmälä, P; Veiranto, M, 2006) |
| "Treatment with rifampin, tobramycin, and ciprofloxacin was started 7 days after subcutaneous implantation of catheters precolonized with 10(4) CFU of S." | 1.32 | Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection. ( Contag, PR; Francis, KP; Kadurugamuwa, JL; Kimura, R; Purchio, T; Sin, LV; Yu, J, 2003) |
| "Sepsis was induced by cecal ligation and puncture (CLP) in Swiss mice using an 18-gauge needle." | 1.32 | Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. ( Amâncio, RT; Bozza, FA; Bozza, PT; Castro-Faria-Neto, HC; David, CM; Gomes, RN; Vianna, RC, 2004) |
| "Both ciprofloxacin treated groups improved radiographically from week 4 to week 10." | 1.32 | Prevention and treatment of experimental osteomyelitis in dogs with ciprofloxacin-loaded crosslinked high amylose starch implants. ( Chouinard, L; Désévaux, C; Dubreuil, P; Huneault, LM; Lussier, B, 2004) |
| "Ciprofloxacin was studied against MSSA1199 and MSSA487." | 1.31 | Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations. ( Coyle, EA; Hershberger, E; Kaatz, GW; Rybak, MJ; Zervos, MJ, 2000) |
| "Two ciprofloxacin-treated cats developed stent blockage at 21 and 42 days, respectively, whereas the other 3 cats had patent stents for the entire study period." | 1.31 | Is prophylactic ciprofloxacin effective in delaying biliary stent blockage? ( Lam, K; Leung, JW; Libby, ED; Liu, Yl; McKay, SG; Morck, DW; Olson, ME, 2000) |
| " Estimates of elimination half-life (T1/2) were not affected by rifabutin (control: 0." | 1.31 | Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ( Li, RC; Liu, XG, 2001) |
| " In the survival study, a dose-response effect of ciprofloxacin on survival was observed (ciprofloxacin: 10 mg/kg, 10%; 50 mg/kg, 26%; and 100 mg/kg, 35%) with the results in the 100-mg/kg-treated group being significant when compared with the 5% survival rate in saline-treated controls (P < ." | 1.30 | The beneficial effects of ciprofloxacin on survival and hepatic regenerative activity in a rat model of fulminant hepatic failure. ( Assy, N; Gauthier, T; Kaita, KD; Meyers, AF; Minuk, GY; Zhang, M, 1998) |
| "Clinafloxacin activity was notably high against Staphylococcus aureus and, against ciprofloxacin-resistant strains, this high activity was maintained in vitro and measurable activity was demonstrated in vivo." | 1.30 | Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies. ( Cohen, MA; Gage, JW; Huband, MD; Roland, GE; Yoder, SL, 1998) |
| "The basic mechanisms underlying reactive arthritis and specifically the joint injury that follows intra-articular Chlamydia trachomatis infection have not been defined." | 1.30 | Synoviocyte-packaged Chlamydia trachomatis induces a chronic aseptic arthritis. ( Chiu, B; Inman, RD, 1998) |
| " The dosing regimen of each drug that yielded serum levels in mice which mimic human therapeutic concentrations of the drugs, were designed." | 1.30 | Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. ( Bui, KQ; Nicolau, DP; Nightingale, CH; Onyeji, CO; Owens, RC; Quintiliani, R, 1999) |
| " These results suggest that either salt of prednisolone, when combined with ciprofloxacin, reduces ocular inflammation without affecting the antimicrobial efficacy of the antibiotic." | 1.29 | Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitis. ( Callegan, MC; Engel, LS; Hill, JM; Hobden, JA; O'Callaghan, RJ, 1993) |
| " If a dosage of 20 mg/kg/day was used, development of acute arthritis was prevented, but some of the animals had positive fecal cultures at the end of experiment." | 1.29 | Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model. ( Gripenberg-Lerche, C; Söderström, KO; Toivanen, A; Toivanen, P; Zhang, Y, 1996) |
| "Ciprofloxacin is a fluoroquinolone antibiotic with broad spectrum bactericidal activity." | 1.29 | The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis. ( Callegan, MC; Engel, LS; Folkens, AT; Hill, JM; O'Callaghan, RJ; Shimomura, Y, 1996) |
| "Amikacin was more effective in reducing the number of organisms in corneas infected with ATCC-6841 than in corneas infected with the patient isolate (p = 0." | 1.28 | Mycobacterium fortuitum keratitis. A comparison of topical ciprofloxacin and amikacin in an animal model. ( Berlin, OG; Bruckner, DA; Holland, GN; Paschal, JF; Phinney, RB; Stevens, RK, 1992) |
| "We studied the pharmacokinetic parameters of four fluoroquinolones--ofloxacin, ciprofloxacin, temafloxacin and sparfloxacin--in a mouse model of Streptococcus pneumoniae-infected lung." | 1.28 | Pharmacokinetics of four fluoroquinolones in an animal model of infected lung. ( Azoulay-Dupuis, E; Bergogne-Bérézin, E; Pocidalo, JJ; Vallée, E, 1991) |
| "Ofloxacin and enoxacin were administered per os and pefloxacin and ciprofloxacin were injected subcutaneously." | 1.28 | [Activity of fluoroquinolones studied on a model of suppurative meningoencephalitis caused by Pseudomonas aeruginosa in mice]. ( Mnatsakanian, VE; Padeĭskaia, EN, 1991) |
| "Treatment with ofloxacin and ciprofloxacin at 50 mg/kg 18 h after infection did not significantly increase survival rates compared with those of untreated controls." | 1.28 | Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. ( Azoulay-Dupuis, E; Bedos, JP; Hardy, DJ; Pocidalo, JJ; Swanson, RN; Vallée, E, 1991) |
| "Ciprofloxacin has a greater than 100-fold in-vitro potency advantage over azithromycin against this organism, but azithromycin (5 mg/kg) produced a greater reduction in cfu than ciprofloxacin (100 mg/kg) at the primary site of infection (liver)." | 1.28 | Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection. ( Girard, AE; Girard, D; Retsema, JA, 1990) |
| "Ciprofloxacin was 1 to 3 twofold dilutions more active than A-61827 against these gram-negative bacteria." | 1.27 | A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. ( Bower, RR; Chu, DT; Fernandes, PB; Hanson, CW; Hardy, DJ; Ramer, NR; Stamm, JM; Swanson, RN, 1988) |
| "Ciprofloxacin has been studied extensively in discriminative animal models of infection, and its efficacy in the treatment of these infections has been compared with that of standard therapy." | 1.27 | Efficacy of ciprofloxacin in animal models of infection: endocarditis, meningitis, and pneumonia. ( Brooks-Fournier, RA; Gerberding, JL; Sande, MA, 1987) |
| "Ciprofloxacin was found to be highly effective against all gram-negative and gram-positive bacteria tested." | 1.27 | Evaluation of ciprofloxacin alone and in combination with other antibiotics in a murine model of thigh muscle infection. ( Haller, I, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (6.83) | 18.7374 |
| 1990's | 52 (18.71) | 18.2507 |
| 2000's | 91 (32.73) | 29.6817 |
| 2010's | 94 (33.81) | 24.3611 |
| 2020's | 22 (7.91) | 2.80 |
| Authors | Studies |
|---|---|
| Heine, HS | 3 |
| Bassett, J | 3 |
| Miller, L | 3 |
| Hartings, JM | 1 |
| Ivins, BE | 3 |
| Pitt, ML | 1 |
| Fritz, D | 1 |
| Norris, SL | 1 |
| Byrne, WR | 1 |
| Griffith, ME | 1 |
| Moon, JE | 1 |
| Johnson, EN | 1 |
| Clark, KP | 1 |
| Hawley, JS | 1 |
| Hospenthal, DR | 1 |
| Murray, CK | 1 |
| Plasencia, V | 1 |
| Borrell, N | 2 |
| Maciá, MD | 2 |
| Moya, B | 1 |
| Pérez, JL | 2 |
| Oliver, A | 2 |
| Adams, DA | 1 |
| Riggs, MM | 1 |
| Donskey, CJ | 1 |
| Park, CH | 1 |
| Lee, J | 1 |
| Jung, HY | 1 |
| Kim, MJ | 1 |
| Lim, SH | 1 |
| Yeo, HT | 1 |
| Choi, EC | 1 |
| Yoon, EJ | 1 |
| Kim, KW | 1 |
| Cha, JH | 1 |
| Kim, SH | 3 |
| Chang, DJ | 1 |
| Kwon, DY | 1 |
| Li, F | 1 |
| Suh, YG | 1 |
| Shilabin, AG | 1 |
| Kasanah, N | 1 |
| Tekwani, BL | 2 |
| Hamann, MT | 1 |
| Bassett, A | 1 |
| Lehoux, D | 2 |
| Arhin, FF | 2 |
| Parr, TR | 2 |
| Moeck, G | 2 |
| Tanaka, KS | 1 |
| Houghton, TJ | 1 |
| Kang, T | 1 |
| Dietrich, E | 1 |
| Delorme, D | 1 |
| Ferreira, SS | 1 |
| Caron, L | 1 |
| Viens, F | 1 |
| Sarmiento, I | 1 |
| Fadhil, I | 1 |
| Laquerre, K | 1 |
| Liu, J | 2 |
| Ostiguy, V | 1 |
| Poirier, H | 1 |
| Rafai Far, A | 1 |
| Chacon-Moreno, BE | 1 |
| Welsh, O | 1 |
| Cavazos-Rocha, N | 1 |
| de la Luz Salazar-Cavazos, M | 1 |
| Garza-Lozano, HG | 1 |
| Said-Fernandez, S | 1 |
| Ocampo-Candiani, J | 1 |
| Vera-Cabrera, L | 1 |
| Samoylenko, V | 1 |
| Ashfaq, MK | 1 |
| Jacob, MR | 1 |
| Khan, SI | 1 |
| Manly, SP | 1 |
| Joshi, VC | 1 |
| Walker, LA | 1 |
| Muhammad, I | 1 |
| Gill, SC | 1 |
| Rubino, CM | 1 |
| Ambrose, PG | 1 |
| Bhavnani, SM | 1 |
| Beaudry, A | 1 |
| Li, J | 2 |
| Stone, KC | 1 |
| Critchley, I | 1 |
| Janjic, N | 1 |
| Avdeef, A | 1 |
| Tam, KY | 1 |
| Crandon, JL | 1 |
| Kuti, JL | 1 |
| Nicolau, DP | 2 |
| Basarab, GS | 1 |
| Manchester, JI | 1 |
| Bist, S | 1 |
| Boriack-Sjodin, PA | 1 |
| Dangel, B | 1 |
| Illingworth, R | 1 |
| Sherer, BA | 1 |
| Sriram, S | 1 |
| Uria-Nickelsen, M | 1 |
| Eakin, AE | 1 |
| Opoku-Temeng, C | 1 |
| Naclerio, GA | 1 |
| Mohammad, H | 1 |
| Dayal, N | 1 |
| Abutaleb, NS | 1 |
| Seleem, MN | 1 |
| Sintim, HO | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 2 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Yang, H | 2 |
| Kundra, S | 1 |
| Chojnacki, M | 1 |
| Liu, K | 1 |
| Fuse, MA | 1 |
| Abouelhassan, Y | 1 |
| Kallifidas, D | 1 |
| Zhang, P | 1 |
| Huang, G | 1 |
| Jin, S | 2 |
| Ding, Y | 1 |
| Luesch, H | 1 |
| Rohde, KH | 1 |
| Dunman, PM | 1 |
| Lemos, JA | 1 |
| Huigens, RW | 1 |
| Yu, JH | 1 |
| Xu, XF | 1 |
| Hou, W | 1 |
| Meng, Y | 1 |
| Huang, MY | 1 |
| Lin, J | 1 |
| Chen, WM | 1 |
| Mahey, N | 1 |
| Tambat, R | 1 |
| Chandal, N | 1 |
| Verma, DK | 1 |
| Thakur, KG | 1 |
| Nandanwar, H | 1 |
| Lin, M | 1 |
| Liu, Y | 1 |
| Gao, J | 2 |
| Wang, D | 1 |
| Xia, D | 1 |
| Liang, C | 1 |
| Li, N | 1 |
| Xu, R | 1 |
| Calum, H | 2 |
| Trøstrup, H | 2 |
| Laulund, AS | 1 |
| Thomsen, K | 2 |
| Christophersen, L | 2 |
| Høiby, N | 2 |
| Moser, C | 2 |
| Çulpan, Y | 1 |
| Keçeci, İ | 1 |
| Sandıkçı, İ | 1 |
| Gökçe, Ş | 1 |
| Göker, H | 1 |
| Özyılmaz Yay, N | 1 |
| Ergelen, R | 1 |
| Akakın, D | 1 |
| Gülhan, R | 1 |
| Sharma, A | 1 |
| Rishi, P | 1 |
| Singh, R | 1 |
| Shafigh Kheljan, F | 1 |
| Sheikhzadeh Hesari, F | 1 |
| Aminifazl, MS | 1 |
| Skurnik, M | 1 |
| Gholadze, S | 1 |
| Zarrini, G | 1 |
| Torres, BGS | 1 |
| Awad, R | 1 |
| Marchand, S | 1 |
| Couet, W | 1 |
| Tewes, F | 2 |
| Jurburg, SD | 1 |
| Cornelissen, JJBWJ | 1 |
| de Boer, P | 1 |
| Smits, MA | 1 |
| Rebel, JMJ | 1 |
| McCloskey, MC | 1 |
| Shaheen, S | 1 |
| Rabago, L | 1 |
| Hulverson, MA | 1 |
| Choi, R | 1 |
| Barrett, LK | 1 |
| Arnold, SLM | 1 |
| Saint-Lu, N | 1 |
| Burdet, C | 1 |
| Sablier-Gallis, F | 1 |
| Corbel, T | 1 |
| Nevière, A | 1 |
| Sayah-Jeanne, S | 1 |
| Pulse, M | 1 |
| Weiss, W | 1 |
| Ferreira, S | 1 |
| Andremont, A | 1 |
| Mentré, F | 1 |
| de Gunzburg, J | 1 |
| Lan, J | 1 |
| Ma, Q | 1 |
| Shao, C | 1 |
| Shan, A | 1 |
| Stratilo, CW | 1 |
| Jager, S | 1 |
| Crichton, M | 1 |
| Blanchard, JD | 4 |
| Perry, MR | 1 |
| Ionin, B | 1 |
| Barnewall, RE | 1 |
| Vassar, ML | 1 |
| Reece, JJ | 1 |
| Park, S | 1 |
| Lemiale, L | 1 |
| Skiadopoulos, MH | 1 |
| Shearer, JD | 1 |
| Savransky, V | 1 |
| Campbell, JL | 1 |
| Fay, MP | 1 |
| Lanning, LL | 1 |
| Hewitt, JA | 1 |
| Bahamondez-Canas, TF | 1 |
| Moraga-Espinoza, D | 1 |
| Smyth, HDC | 1 |
| Watts, AB | 1 |
| Grygorcewicz, B | 1 |
| Roszak, M | 1 |
| Golec, P | 1 |
| Śleboda-Taront, D | 1 |
| Łubowska, N | 1 |
| Górska, M | 1 |
| Jursa-Kulesza, J | 1 |
| Rakoczy, R | 1 |
| Wojciuk, B | 1 |
| Dołęgowska, B | 1 |
| Vietri, NJ | 2 |
| Tobery, SA | 2 |
| Chabot, DJ | 1 |
| Ingavale, S | 1 |
| Somerville, BC | 1 |
| Miller, JA | 1 |
| Schellhase, CW | 1 |
| Twenhafel, NA | 2 |
| Fetterer, DP | 1 |
| Cote, CK | 1 |
| Klimko, CP | 1 |
| Boyer, AE | 1 |
| Woolfitt, AR | 1 |
| Barr, JR | 1 |
| Wright, ME | 2 |
| Friedlander, AM | 2 |
| Goldshtein, H | 1 |
| Muhire, A | 1 |
| Petel Légaré, V | 1 |
| Pushett, A | 1 |
| Rotkopf, R | 1 |
| Shefner, JM | 1 |
| Peterson, RT | 1 |
| Armstrong, GAB | 1 |
| Russek-Blum, N | 1 |
| Wang, L | 1 |
| Tkhilaishvili, T | 1 |
| Bernal Andres, B | 1 |
| Trampuz, A | 1 |
| Gonzalez Moreno, M | 1 |
| Stern, JM | 1 |
| Burk, RD | 1 |
| Asplin, J | 1 |
| Krieger, NS | 1 |
| Suadicani, SO | 1 |
| Wang, Y | 2 |
| Usyk, M | 1 |
| Lee, JA | 1 |
| Chen, L | 1 |
| Becker, J | 1 |
| Chan, M | 1 |
| Bushinsky, DA | 1 |
| Liao, CC | 1 |
| Yu, HP | 1 |
| Yang, SC | 1 |
| Alalaiwe, A | 1 |
| Dai, YS | 1 |
| Liu, FC | 1 |
| Fang, JY | 1 |
| Dey, R | 1 |
| Bishayi, B | 1 |
| Richter, K | 1 |
| Thomas, N | 1 |
| Zhang, G | 1 |
| Prestidge, CA | 1 |
| Coenye, T | 1 |
| Wormald, PJ | 1 |
| Vreugde, S | 1 |
| Rossi, O | 1 |
| Dybowski, R | 1 |
| Maskell, DJ | 1 |
| Grant, AJ | 1 |
| Restif, O | 1 |
| Mastroeni, P | 1 |
| Cho, DY | 1 |
| Lim, DJ | 1 |
| Mackey, C | 1 |
| Skinner, D | 1 |
| Weeks, C | 1 |
| Gill, GS | 1 |
| Hergenrother, RW | 1 |
| Swords, WE | 1 |
| Woodworth, BA | 1 |
| Wardlow, R | 1 |
| Sahoo, K | 1 |
| Dugat, D | 1 |
| Malayer, J | 1 |
| Ranjan, A | 1 |
| Sanchez, MF | 1 |
| Breda, SA | 1 |
| Soria, EA | 1 |
| Tártara, LI | 1 |
| Manzo, RH | 1 |
| Olivera, ME | 1 |
| Ben-Shmuel, A | 1 |
| Glinert, I | 2 |
| Sittner, A | 2 |
| Bar-David, E | 2 |
| Schlomovitz, J | 2 |
| Brosh, T | 1 |
| Kobiler, D | 2 |
| Weiss, S | 4 |
| Levy, H | 2 |
| Matsubara, A | 1 |
| Oda, S | 1 |
| Akai, S | 1 |
| Tsuneyama, K | 1 |
| Yokoi, T | 1 |
| LeMaire, SA | 1 |
| Zhang, L | 1 |
| Luo, W | 1 |
| Ren, P | 1 |
| Azares, AR | 1 |
| Zhang, C | 1 |
| Coselli, JS | 1 |
| Shen, YH | 1 |
| Sundaramoorthy, NS | 1 |
| Mitra, K | 1 |
| Ganesh, JS | 1 |
| Makala, H | 1 |
| Lotha, R | 1 |
| Bhanuvalli, SR | 1 |
| Ulaganathan, V | 2 |
| Tiru, V | 1 |
| Sivasubramanian, A | 1 |
| Nagarajan, S | 2 |
| Wang, X | 3 |
| Zheng, Y | 1 |
| Ma, Y | 1 |
| Du, L | 2 |
| Chu, F | 1 |
| Gu, H | 1 |
| Dahlgren, RA | 1 |
| Li, Y | 3 |
| Wang, H | 2 |
| Zhang, CY | 1 |
| Wang, Z | 1 |
| Yang, R | 1 |
| Sabharwal, V | 1 |
| Shlykova, N | 1 |
| Okonkwo, OS | 1 |
| Pelton, SI | 1 |
| Kohane, DS | 1 |
| Haugan, MS | 1 |
| Løbner-Olesen, A | 1 |
| Frimodt-Møller, N | 2 |
| Elhosseiny, NM | 1 |
| Elhezawy, NB | 1 |
| Attia, AS | 1 |
| Winarsih, S | 1 |
| Kosasih, T | 1 |
| Putera, MA | 1 |
| Rahmadhiani, N | 1 |
| Poernomo, EL | 1 |
| Runtuk, KS | 1 |
| Oswari, MV | 1 |
| Chen, K | 1 |
| Chan, EWC | 1 |
| Chen, S | 1 |
| Laulund, ASB | 1 |
| Lerche, CJ | 1 |
| Zhao, R | 1 |
| Wang, Q | 1 |
| Hu, XX | 1 |
| Nie, TY | 1 |
| Yang, XY | 1 |
| Li, CR | 1 |
| Lu, X | 1 |
| Jiang, JD | 1 |
| Pang, J | 1 |
| You, XF | 1 |
| Kim, SE | 1 |
| Kim, HK | 1 |
| Choi, SM | 1 |
| Yu, Y | 1 |
| Kim, UJ | 1 |
| Darboe, KS | 1 |
| Kang, SJ | 1 |
| Park, KH | 1 |
| Kang, G | 1 |
| Kim, YR | 1 |
| Rhee, JH | 2 |
| Jung, SI | 1 |
| Jang, HC | 1 |
| Nichols, DP | 1 |
| Caceres, S | 1 |
| Caverly, L | 1 |
| Fratelli, C | 1 |
| Malcolm, K | 1 |
| Poch, KR | 1 |
| Saavedra, M | 1 |
| Solomon, G | 1 |
| Taylor-Cousar, J | 1 |
| Moskowitz, S | 1 |
| Nick, JA | 1 |
| Domínguez-Herrera, J | 2 |
| Velasco, C | 1 |
| Docobo-Pérez, F | 3 |
| Rodríguez-Martínez, JM | 2 |
| López-Rojas, R | 2 |
| Briales, A | 1 |
| Pichardo, C | 1 |
| Díaz-de-Alba, P | 2 |
| Rodríguez-Baño, J | 1 |
| Pascual, A | 2 |
| Pachón, J | 2 |
| Stundick, MV | 1 |
| Albrecht, MT | 1 |
| Houchens, CR | 1 |
| Smith, AP | 1 |
| Dreier, TM | 1 |
| Larsen, JC | 1 |
| Gnanadhas, DP | 1 |
| Ben Thomas, M | 1 |
| Elango, M | 1 |
| Raichur, AM | 1 |
| Chakravortty, D | 1 |
| Lu, Q | 2 |
| Yu, J | 3 |
| Bao, L | 1 |
| Ran, T | 2 |
| Zhong, H | 1 |
| Wang, JH | 1 |
| Sun, GF | 1 |
| Zhang, J | 1 |
| Shao, CW | 1 |
| Zuo, CJ | 1 |
| Hao, J | 1 |
| Zheng, JM | 1 |
| Feng, XY | 1 |
| Guillard, T | 1 |
| Cambau, E | 1 |
| Chau, F | 1 |
| Massias, L | 1 |
| de Champs, C | 1 |
| Fantin, B | 1 |
| Wang, J | 1 |
| Li, B | 1 |
| Dou, J | 1 |
| Hao, Q | 1 |
| Tian, Y | 1 |
| Zhou, C | 1 |
| Sun, Z | 1 |
| Shi, J | 1 |
| Liu, C | 1 |
| Jin, Y | 1 |
| Li, K | 1 |
| Chen, R | 1 |
| Wu, W | 1 |
| Fernandez, R | 1 |
| Tsivkovskaia, N | 1 |
| Harrop-Jones, A | 1 |
| Hou, HJ | 1 |
| Dellamary, L | 1 |
| Dolan, DF | 1 |
| Altschuler, RA | 1 |
| LeBel, C | 1 |
| Piu, F | 1 |
| Hamblin, KA | 3 |
| Armstrong, SJ | 2 |
| Barnes, KB | 1 |
| Davies, C | 1 |
| Wong, JP | 3 |
| Harding, SV | 1 |
| Simpson, AJ | 2 |
| Atkins, HS | 2 |
| Li, SA | 1 |
| Xiang, Y | 1 |
| Wang, YJ | 1 |
| Lee, WH | 1 |
| Zhang, Y | 3 |
| Norville, IH | 1 |
| Hatch, GJ | 1 |
| Bewley, KR | 1 |
| Atkinson, DJ | 1 |
| Pitman, JK | 1 |
| Rayner, E | 1 |
| Hall, G | 1 |
| Vipond, J | 1 |
| Atkins, TP | 1 |
| Gupta, P | 1 |
| Chhibber, S | 3 |
| Harjai, K | 3 |
| Hui, A | 1 |
| Willcox, M | 1 |
| Jones, L | 1 |
| Zangari, T | 1 |
| Melton-Celsa, AR | 1 |
| Panda, A | 1 |
| Smith, MA | 1 |
| Tatarov, I | 1 |
| De Tolla, L | 1 |
| O'Brien, AD | 1 |
| Saini, H | 2 |
| Kwan, BW | 1 |
| Chowdhury, N | 1 |
| Wood, TK | 1 |
| Tamm, TI | 1 |
| Nepomnyashchiy, VV | 1 |
| Shakalova, EA | 1 |
| Dvornik, IA | 1 |
| Altboum, Z | 1 |
| Kaiser, P | 1 |
| Regoes, RR | 1 |
| Hardt, WD | 2 |
| Taslidere, E | 1 |
| Dogan, Z | 1 |
| Elbe, H | 1 |
| Vardi, N | 1 |
| Cetin, A | 1 |
| Turkoz, Y | 1 |
| Cheng, C | 1 |
| He, Y | 1 |
| Wanek, T | 1 |
| Halilbasic, E | 1 |
| Visentin, M | 1 |
| Mairinger, S | 1 |
| Römermann, K | 1 |
| Stieger, B | 1 |
| Kuntner, C | 1 |
| Müller, M | 1 |
| Langer, O | 1 |
| Trauner, M | 1 |
| Vadekeetil, A | 1 |
| Sung, PH | 1 |
| Chiang, HJ | 1 |
| Chen, CH | 1 |
| Chen, YL | 2 |
| Huang, TH | 1 |
| Zhen, YY | 1 |
| Chang, MW | 1 |
| Liu, CF | 1 |
| Chung, SY | 1 |
| Chai, HT | 1 |
| Sun, CK | 1 |
| Yip, HK | 1 |
| Roy, DC | 1 |
| Tomblyn, S | 1 |
| Isaac, KM | 1 |
| Kowalczewski, CJ | 1 |
| Burmeister, DM | 1 |
| Burnett, LR | 1 |
| Christy, RJ | 1 |
| Eskandari, M | 1 |
| Ghalyanchi Langeroudi, A | 1 |
| Zeighami, H | 1 |
| Rostami, A | 1 |
| Kazemi, M | 1 |
| Eyni, H | 1 |
| Shokri, S | 1 |
| Obregón-Henao, A | 1 |
| Wallach, JB | 1 |
| North, EJ | 1 |
| Lee, RE | 1 |
| Gonzalez-Juarrero, M | 1 |
| Schnappinger, D | 1 |
| Jackson, M | 1 |
| Machuca, J | 1 |
| Ortiz, M | 1 |
| Recacha, E | 1 |
| Lowrence, RC | 1 |
| Raman, T | 1 |
| Makala, HV | 1 |
| Subramaniapillai, SG | 1 |
| Kuppuswamy, AA | 1 |
| Mani, A | 1 |
| Chittoor Neelakantan, S | 1 |
| Atala, A | 1 |
| Wu, D | 1 |
| Zhang, W | 1 |
| Wang, T | 1 |
| Lin, T | 1 |
| Jin, X | 1 |
| Xie, X | 1 |
| Guo, J | 1 |
| Cao, Y | 1 |
| Wu, R | 1 |
| Sibila, O | 1 |
| Luna, CM | 1 |
| Agustí, C | 1 |
| Baquero, S | 1 |
| Gando, S | 1 |
| Patrón, JR | 1 |
| Morato, JG | 1 |
| Absi, R | 1 |
| Bassi, N | 1 |
| Torres, A | 1 |
| Mansour, M | 1 |
| Mansour, S | 1 |
| Mortada, ND | 1 |
| Abd Elhady, SS | 1 |
| Bashir, S | 1 |
| Jamshaid, M | 1 |
| Ahmad, B | 1 |
| Iqbal, J | 1 |
| Karicherla, P | 1 |
| Hobden, JA | 6 |
| Purcell, BK | 1 |
| Rasmussen, SL | 1 |
| Leffel, EK | 1 |
| Kellogg, MD | 1 |
| Webster, WM | 1 |
| Yazici, A | 1 |
| Naiboglu, B | 1 |
| Oysu, C | 1 |
| Toros, SZ | 1 |
| Noseri, H | 1 |
| Karaca, CT | 1 |
| Egeli, E | 1 |
| Zhang, Q | 1 |
| Donohue-Rolfe, A | 1 |
| Krautz-Peterson, G | 1 |
| Sevo, M | 1 |
| Parry, N | 1 |
| Abeijon, C | 1 |
| Tzipori, S | 1 |
| Thomas, RJ | 1 |
| Webber, D | 1 |
| Collinge, A | 1 |
| Stagg, AJ | 4 |
| Bailey, SC | 1 |
| Nunez, A | 1 |
| Gates, A | 1 |
| Jayasekera, PN | 1 |
| Taylor, RR | 3 |
| Eley, S | 1 |
| Titball, RW | 3 |
| Kavanagh, KR | 1 |
| Parham, K | 1 |
| Schoem, SR | 1 |
| Stangogiannis-Druya, E | 1 |
| Stangogiannis-Druya, C | 1 |
| Naranjo-Tackman, R | 1 |
| Vanzzini, V | 1 |
| Villar-Kurí, J | 1 |
| Sohn, DW | 3 |
| Han, CH | 4 |
| Jung, YS | 1 |
| Kim, SI | 1 |
| Kim, SW | 3 |
| Cho, YH | 4 |
| Nakamura, S | 1 |
| Yanagihara, K | 2 |
| Araki, N | 1 |
| Morinaga, Y | 1 |
| Izumikawa, K | 1 |
| Seki, M | 1 |
| Kakeya, H | 2 |
| Yamamoto, Y | 1 |
| Kamihira, S | 1 |
| Kohno, S | 2 |
| Kapusuz, Z | 1 |
| Keles, E | 1 |
| Alpay, HC | 1 |
| Karlidag, T | 1 |
| Kaygusuz, I | 1 |
| Uzunlar, AK | 1 |
| Orhan, I | 1 |
| Yalcin, S | 1 |
| Zhang, H | 1 |
| Jiang, NY | 1 |
| Zhu, L | 1 |
| Kishii, R | 1 |
| Takei, M | 1 |
| Nakano, Y | 1 |
| Maybauer, MO | 1 |
| Maybauer, DM | 1 |
| Enkhbaatar, P | 1 |
| Traber, DL | 1 |
| Kowalski, RP | 3 |
| Romanowski, EG | 4 |
| Mah, FS | 4 |
| Shanks, RM | 1 |
| Gordon, YJ | 4 |
| Joshi, PV | 1 |
| Shirkhedkar, AA | 1 |
| Prakash, K | 1 |
| Maheshwari, VL | 1 |
| Ha, US | 1 |
| Lee, HR | 1 |
| Lee, SJ | 3 |
| Kim, HW | 1 |
| Lee, CB | 1 |
| Lin, HC | 1 |
| Yang, YY | 1 |
| Tsai, TH | 1 |
| Huang, CM | 1 |
| Huang, YT | 1 |
| Lee, FY | 1 |
| Liu, TT | 1 |
| Lee, SD | 1 |
| Growcott, EJ | 1 |
| Coulthard, A | 1 |
| Amison, R | 1 |
| Hardaker, EL | 1 |
| Saxena, V | 1 |
| Malt, L | 1 |
| Jones, P | 1 |
| Grevot, A | 1 |
| Poll, C | 1 |
| Osborne, C | 1 |
| Banner, KH | 1 |
| Ngomba, RT | 1 |
| Santolini, I | 1 |
| Biagioni, F | 1 |
| Molinaro, G | 1 |
| Simonyi, A | 1 |
| van Rijn, CM | 1 |
| D'Amore, V | 1 |
| Mastroiacovo, F | 1 |
| Olivieri, G | 1 |
| Gradini, R | 1 |
| Ferraguti, F | 1 |
| Battaglia, G | 1 |
| Bruno, V | 1 |
| Puliti, A | 1 |
| van Luijtelaar, G | 1 |
| Nicoletti, F | 1 |
| Le, UN | 1 |
| Kim, HS | 1 |
| Kwon, JS | 1 |
| Kim, MY | 1 |
| Nguyen, VH | 1 |
| Jiang, SN | 1 |
| Lee, BI | 1 |
| Hong, Y | 1 |
| Shin, MG | 1 |
| Bom, HS | 1 |
| Ahn, Y | 1 |
| Gambhir, SS | 1 |
| Choy, HE | 1 |
| Min, JJ | 1 |
| Dattaray, P | 1 |
| Pudrith, C | 1 |
| Nyc, MA | 1 |
| Martin, D | 1 |
| Kim, YH | 1 |
| Jahng, P | 1 |
| Chung, YS | 1 |
| Wall, GM | 1 |
| Jung, T | 1 |
| Nelson, M | 2 |
| Stevens, DJ | 1 |
| Brown, MA | 1 |
| Pearce, PC | 1 |
| Lever, MS | 3 |
| Liu, MT | 1 |
| Sheng, MY | 1 |
| Scarparo, RK | 1 |
| Dondoni, L | 1 |
| Böttcher, DE | 1 |
| Grecca, FS | 1 |
| Rockenbach, MI | 1 |
| Batista, EL | 1 |
| Sánchez-Céspedes, J | 1 |
| Vila, J | 1 |
| Gbotosho, GO | 1 |
| Happi, CT | 1 |
| Woranola, O | 1 |
| Abiodun, OO | 1 |
| Sowunmi, A | 1 |
| Oduola, AM | 1 |
| Wilson, CN | 1 |
| Vance, CO | 1 |
| Doyle, TM | 1 |
| Brink, DS | 1 |
| Matuschak, GM | 1 |
| Lechner, AJ | 1 |
| Caliskan, B | 1 |
| Guven, A | 1 |
| Ozler, M | 1 |
| Cayci, T | 1 |
| Ozcan, A | 1 |
| Bedir, O | 1 |
| Surer, I | 1 |
| Korkmaz, A | 1 |
| Crull, K | 1 |
| Selvaraj, N | 1 |
| Lakshmanan, B | 1 |
| Mazumder, PM | 1 |
| Karuppasamy, M | 1 |
| Jena, SS | 1 |
| Pattnaik, AK | 1 |
| Silva, RC | 1 |
| Dohar, JE | 3 |
| Hebda, PA | 2 |
| Arslan, N | 1 |
| Tepe, D | 1 |
| Taştan, E | 1 |
| Demirci, M | 1 |
| Caydere, M | 1 |
| Ustun, H | 1 |
| Oguz, H | 2 |
| Wouthuyzen-Bakker, M | 1 |
| Bijvelds, MJ | 1 |
| de Jonge, HR | 1 |
| De Lisle, RC | 2 |
| Burgerhof, JG | 1 |
| Verkade, HJ | 1 |
| Veach, RA | 1 |
| Zienkiewicz, J | 1 |
| Collins, RD | 1 |
| Hawiger, J | 1 |
| Endt, K | 1 |
| Maier, L | 1 |
| Käppeli, R | 1 |
| Barthel, M | 1 |
| Misselwitz, B | 1 |
| Kremer, M | 1 |
| Saribas, Z | 1 |
| Ergun, H | 1 |
| Mamuk, S | 1 |
| Köseoglu-Eser, O | 1 |
| Melli, M | 1 |
| Gao, H | 2 |
| Sandermann, J | 2 |
| Prag, J | 2 |
| Lund, L | 2 |
| Lindholt, JS | 2 |
| Neupane, GP | 1 |
| Kim, DM | 1 |
| Yun, NR | 1 |
| Shin, SH | 1 |
| Lim, SC | 1 |
| Choi, CH | 2 |
| Lee, DH | 1 |
| Komor, U | 1 |
| Bielecki, P | 1 |
| Loessner, H | 1 |
| Rohde, M | 1 |
| Wolf, K | 1 |
| Westphal, K | 1 |
| Häussler, S | 1 |
| Jakobsen, L | 1 |
| Cattoir, V | 1 |
| Jensen, KS | 1 |
| Hammerum, AM | 1 |
| Nordmann, P | 1 |
| Yoshikawa, T | 1 |
| Takahashi, Y | 1 |
| Kawaguchi, H | 1 |
| Utsunomiya, S | 1 |
| Miura, N | 1 |
| Izumi, H | 1 |
| Miyoshi, N | 1 |
| Tanimoto, A | 1 |
| Jang, CH | 1 |
| Cho, YB | 1 |
| Lee, JS | 1 |
| Kang, SI | 1 |
| Breidenstein, EB | 1 |
| Janot, L | 1 |
| Strehmel, J | 1 |
| Fernandez, L | 1 |
| Taylor, PK | 1 |
| Kukavica-Ibrulj, I | 1 |
| Gellatly, SL | 1 |
| Levesque, RC | 1 |
| Overhage, J | 1 |
| Hancock, RE | 1 |
| Durek, C | 1 |
| Jurczok, A | 1 |
| Werner, H | 1 |
| Jocham, D | 1 |
| Bohle, A | 1 |
| Fuursted, K | 1 |
| Schumacher, H | 1 |
| Bamias, G | 1 |
| Marini, M | 1 |
| Moskaluk, CA | 1 |
| Odashima, M | 1 |
| Ross, WG | 1 |
| Rivera-Nieves, J | 1 |
| Cominelli, F | 1 |
| Ellbogen, MH | 1 |
| Olsen, KM | 1 |
| Gentry-Nielsen, MJ | 1 |
| Preheim, LC | 1 |
| Tungsiripat, T | 1 |
| Sarayba, MA | 2 |
| Kaufman, MB | 1 |
| Sweet, PM | 2 |
| Taban, M | 2 |
| Carpenter, TR | 1 |
| McDonnell, PJ | 2 |
| Kadurugamuwa, JL | 1 |
| Sin, LV | 1 |
| Francis, KP | 1 |
| Kimura, R | 1 |
| Purchio, T | 1 |
| Contag, PR | 1 |
| Blasetti, KL | 1 |
| Schnell, G | 1 |
| Conley, J | 1 |
| Schofield, LN | 1 |
| Collins, DM | 1 |
| Kawakami, RP | 1 |
| Buddle, BM | 1 |
| Wards, BJ | 1 |
| de Lisle, GW | 1 |
| Domenech, A | 1 |
| Cabellos, C | 1 |
| Ribes, S | 1 |
| Tubau, F | 1 |
| Viladrich, PF | 1 |
| Liñares, J | 1 |
| Gudiol, F | 1 |
| Barequet, IS | 1 |
| Denton, P | 1 |
| Osterhout, GJ | 1 |
| Tuli, S | 1 |
| O'Brien, TP | 2 |
| Vianna, RC | 1 |
| Gomes, RN | 1 |
| Bozza, FA | 1 |
| Amâncio, RT | 1 |
| Bozza, PT | 1 |
| David, CM | 1 |
| Castro-Faria-Neto, HC | 1 |
| Rhee, MK | 1 |
| Ritterband, DC | 1 |
| Hyon, JY | 1 |
| Joo, MJ | 1 |
| Hose, S | 1 |
| Sinha, D | 1 |
| Dick, JD | 1 |
| Meyerhoff, A | 1 |
| Albrecht, R | 1 |
| Meyer, JM | 1 |
| Dionne, P | 1 |
| Higgins, K | 1 |
| Murphy, D | 1 |
| Huneault, LM | 1 |
| Lussier, B | 1 |
| Dubreuil, P | 1 |
| Chouinard, L | 1 |
| Désévaux, C | 1 |
| Steward, J | 2 |
| Russell, P | 3 |
| Beedham, RJ | 2 |
| Brooks, TJ | 2 |
| Alkorta, M | 1 |
| Giménez, MJ | 1 |
| Vicente, D | 1 |
| Aguilar, L | 1 |
| Pérez-Trallero, E | 1 |
| Jensen, H | 1 |
| Zerouala, C | 1 |
| Carrier, M | 1 |
| Short, B | 1 |
| Koort, JK | 2 |
| Mäkinen, TJ | 2 |
| Suokas, E | 2 |
| Veiranto, M | 2 |
| Jalava, J | 2 |
| Knuuti, J | 1 |
| Törmälä, P | 2 |
| Aro, HT | 2 |
| Ozbilge, H | 1 |
| Oguz, E | 1 |
| Gurkan, T | 1 |
| Cirz, RT | 1 |
| Chin, JK | 1 |
| Andes, DR | 1 |
| de Crécy-Lagard, V | 1 |
| Craig, WA | 1 |
| Romesberg, FE | 1 |
| Lee, YS | 1 |
| Kang, SH | 2 |
| Shin, OR | 1 |
| Sim, YC | 1 |
| Perrin-Guyomard, A | 1 |
| Poul, JM | 1 |
| Corpet, DE | 1 |
| Sanders, P | 1 |
| Fernández, AH | 1 |
| Bartholomew, M | 1 |
| Gülçubuk, A | 1 |
| Sönmez, K | 1 |
| Gürel, A | 1 |
| Altunatmaz, K | 1 |
| Gürler, N | 1 |
| Aydin, S | 2 |
| Oksüz, L | 1 |
| Uzun, H | 2 |
| Güzel, O | 1 |
| Shamie, N | 1 |
| Reiser, BJ | 1 |
| Graff, JM | 1 |
| Kesler-Diaz, A | 1 |
| Osann, KE | 1 |
| Giacometti, A | 1 |
| Cirioni, O | 1 |
| Ghiselli, R | 1 |
| Orlando, F | 1 |
| Mocchegiani, F | 1 |
| Silvestri, C | 1 |
| Licci, A | 1 |
| De Fusco, M | 1 |
| Provinciali, M | 1 |
| Saba, V | 1 |
| Scalise, G | 1 |
| Piercy, T | 1 |
| Brook, I | 1 |
| Germana, A | 1 |
| Giraldo, DE | 1 |
| Camp-Hyde, TD | 1 |
| Bolduc, DL | 1 |
| Foriska, MA | 1 |
| Elliott, TB | 1 |
| Thakar, JH | 1 |
| Shoemaker, MO | 1 |
| Jackson, WE | 1 |
| Ledney, GD | 1 |
| Roach, EA | 1 |
| Norkina, O | 1 |
| Donnenfeld, RS | 1 |
| Perry, HD | 1 |
| Solomon, R | 1 |
| Jensen, HG | 1 |
| Stein, J | 1 |
| Snyder, RW | 1 |
| Wittpenn, JR | 1 |
| Donnenfeld, ED | 1 |
| Caballero, AR | 1 |
| Marquart, ME | 1 |
| O'Callaghan, RJ | 8 |
| Thibodeaux, BA | 1 |
| Johnston, KH | 1 |
| Dajcs, JJ | 1 |
| Orhan, Z | 1 |
| Cevher, E | 1 |
| Mülazimoglu, L | 1 |
| Gürcan, D | 1 |
| Alper, M | 1 |
| Araman, A | 1 |
| Ozsoy, Y | 1 |
| Segura, M | 1 |
| Gómez, C | 1 |
| Dhaliwal, DK | 1 |
| Yates, KA | 2 |
| Yağci, R | 1 |
| Oflu, Y | 1 |
| Dinçel, A | 1 |
| Kaya, E | 1 |
| Yağci, S | 1 |
| Bayar, B | 1 |
| Duman, S | 1 |
| Bozkurt, A | 1 |
| García-Alvarez, F | 2 |
| Monzón, M | 2 |
| Grasa, JM | 1 |
| Laclériga, A | 2 |
| Amorena, B | 2 |
| García-Alvarez, I | 1 |
| Navarro-Zorraquino, M | 1 |
| Alvarez, FG | 1 |
| Onlen, Y | 1 |
| Tamer, C | 1 |
| Oksuz, H | 1 |
| Duran, N | 1 |
| Altug, ME | 1 |
| Yakan, S | 1 |
| Yuksel, S | 1 |
| Schwarz, M | 1 |
| Poch, B | 1 |
| Isenmann, R | 1 |
| Kriese, D | 1 |
| Rozdzinski, E | 1 |
| Beger, HG | 1 |
| Gansauge, F | 1 |
| Milberg, P | 1 |
| Hilker, E | 1 |
| Ramtin, S | 1 |
| Cakir, Y | 1 |
| Stypmann, J | 1 |
| Engelen, MA | 1 |
| Mönnig, G | 1 |
| Osada, N | 1 |
| Breithardt, G | 1 |
| Haverkamp, W | 1 |
| Eckardt, L | 1 |
| Aksu, B | 1 |
| Inan, M | 1 |
| Kanter, M | 1 |
| Oz Puyan, F | 1 |
| Durmus-Altun, G | 1 |
| Gurcan, S | 1 |
| Ayvaz, S | 1 |
| Pul, M | 1 |
| Demir, A | 1 |
| Türker, P | 1 |
| Onol, FF | 1 |
| Sirvanci, S | 1 |
| Findik, A | 1 |
| Tarcan, T | 1 |
| Sripriya, R | 1 |
| Kumar, MS | 1 |
| Ahmed, MR | 1 |
| Sehgal, PK | 1 |
| Bu, P | 1 |
| Riske, PS | 1 |
| Zaya, NE | 1 |
| Carey, R | 1 |
| Bouchard, CS | 1 |
| Alvarez, H | 1 |
| Castro, C | 1 |
| Moujir, L | 1 |
| Perera, A | 1 |
| Delgado, A | 1 |
| Soriano, I | 1 |
| Evora, C | 1 |
| Sánchez, E | 1 |
| Yang, CH | 1 |
| Huang, HC | 1 |
| Shieh, CC | 1 |
| Yu, WL | 1 |
| Cheng, KC | 1 |
| Chen, CC | 1 |
| Chang, ST | 1 |
| Chuang, YC | 1 |
| Kanellakopoulou, K | 1 |
| Thivaios, GC | 1 |
| Kolia, M | 1 |
| Dontas, I | 1 |
| Nakopoulou, L | 1 |
| Dounis, E | 1 |
| Giamarellos-Bourboulis, EJ | 1 |
| Andreopoulos, A | 1 |
| Karagiannakos, P | 1 |
| Giamarellou, H | 1 |
| Owusu-Ababio, G | 1 |
| Rogers, JA | 1 |
| Morck, DW | 2 |
| Olson, ME | 2 |
| Engel, LS | 4 |
| Callegan, MC | 5 |
| Reidy, JJ | 2 |
| Hill, JM | 7 |
| Guzek, JP | 1 |
| Chacko, D | 1 |
| Kettering, JD | 1 |
| Wessels, IF | 1 |
| Aprecio, RM | 1 |
| D'iakov, SI | 2 |
| Katsalukha, VV | 1 |
| Lebedeva, IK | 2 |
| Lukashina, AV | 1 |
| Raĭskaia, VA | 1 |
| Lin, R | 2 |
| Holland, GN | 3 |
| Helm, CJ | 2 |
| Elias, SJ | 1 |
| Berlin, OG | 3 |
| Bruckner, DA | 3 |
| Weiss, LM | 1 |
| Wittner, M | 1 |
| Wasserman, S | 1 |
| Oz, HS | 1 |
| Retsema, J | 1 |
| Tanowitz, HB | 1 |
| Whitman, MS | 1 |
| Pitsakis, PG | 1 |
| Zausner, A | 1 |
| Livornese, LL | 1 |
| Osborne, AJ | 1 |
| Johnson, CC | 1 |
| Levison, ME | 1 |
| Lauffenburger, MD | 1 |
| Cohen, KL | 1 |
| Chakrabarti, MK | 1 |
| Bhattacharya, MK | 1 |
| Sinha, AK | 1 |
| Chatterjee, DC | 1 |
| Bhattacharya, SK | 1 |
| Nitsche, D | 1 |
| Schulze, C | 1 |
| Oesser, S | 1 |
| Dalhoff, A | 1 |
| Sack, M | 1 |
| Gripenberg-Lerche, C | 1 |
| Söderström, KO | 1 |
| Toivanen, A | 2 |
| Toivanen, P | 1 |
| Kim, IT | 1 |
| Chung, KH | 1 |
| Koo, BS | 1 |
| Meng, X | 1 |
| Pei, Y | 1 |
| Nightingale, CH | 2 |
| Quintiliani, R | 2 |
| Behrens-Baumann, W | 1 |
| Alfaro, DV | 2 |
| Hudson, SJ | 1 |
| offele, JJ | 1 |
| Bevin, AA | 1 |
| Mines, M | 1 |
| Laughlin, RM | 1 |
| Schoderbek, RJ | 1 |
| Folkens, AT | 1 |
| Shimomura, Y | 1 |
| Davis, J | 1 |
| Kim, S | 1 |
| Bia, F | 1 |
| Bogard, JF | 1 |
| Briggs, JW | 1 |
| Liggett, PE | 1 |
| Sato, A | 1 |
| Kitazawa, H | 1 |
| Hayakawa, H | 1 |
| Chida, K | 1 |
| Iwata, M | 1 |
| Kaita, KD | 1 |
| Assy, N | 1 |
| Gauthier, T | 1 |
| Zhang, M | 1 |
| Meyers, AF | 1 |
| Minuk, GY | 1 |
| Eley, SM | 2 |
| Green, M | 1 |
| Bell, DL | 2 |
| Rogers, D | 1 |
| Whittington, D | 1 |
| Shapiro, MA | 1 |
| Sesnie, JC | 1 |
| Desaty, TM | 1 |
| Griffin, TJ | 1 |
| Heifetz, CL | 1 |
| Fulop, MJ | 1 |
| Cohen, MA | 1 |
| Huband, MD | 1 |
| Yoder, SL | 1 |
| Gage, JW | 1 |
| Roland, GE | 1 |
| Moreau, JM | 1 |
| Green, LC | 1 |
| Ramchandani, M | 1 |
| Robinson, D | 1 |
| Alper, CM | 1 |
| Rose, EA | 1 |
| Doyle, WJ | 1 |
| Casselbrant, ML | 1 |
| Kenna, MA | 1 |
| Bluestone, CD | 1 |
| Opal, SM | 3 |
| Jhung, JW | 1 |
| Keith, JC | 1 |
| Palardy, JE | 2 |
| Parejo, NA | 1 |
| Young, LD | 1 |
| Bhattacharjee, A | 1 |
| Inman, RD | 1 |
| Chiu, B | 1 |
| Onyeji, CO | 1 |
| Bui, KQ | 1 |
| Owens, RC | 1 |
| Lewis, DA | 1 |
| Zhang, X | 1 |
| McDaniel, AD | 1 |
| Wolf, LE | 1 |
| Keusch, GT | 1 |
| Waldor, MK | 1 |
| Acheson, DW | 1 |
| Hans, W | 1 |
| Schölmerich, J | 1 |
| Gross, V | 1 |
| Falk, W | 1 |
| Hershberger, E | 1 |
| Coyle, EA | 1 |
| Kaatz, GW | 1 |
| Zervos, MJ | 1 |
| Rybak, MJ | 1 |
| Wright, CG | 1 |
| Pawlowski, KS | 1 |
| Roland, PS | 1 |
| Meyerhoff, WL | 1 |
| Bubnov, VP | 1 |
| Sidorenko, SV | 1 |
| Moskalenko, VI | 1 |
| Leung, JW | 1 |
| Libby, ED | 1 |
| McKay, SG | 1 |
| Liu, Yl | 1 |
| Lam, K | 1 |
| Bakker-Woudenberg, IA | 2 |
| ten Kate, MT | 1 |
| Guo, L | 1 |
| Working, P | 1 |
| Mouton, JW | 1 |
| Capdevila, JA | 1 |
| Gavaldà, J | 1 |
| Fortea, J | 1 |
| López, P | 1 |
| Martin, MT | 1 |
| Gomis, X | 1 |
| Pahissa, A | 1 |
| Shalit, I | 1 |
| Kletter, Y | 1 |
| Halperin, D | 1 |
| Waldman, D | 1 |
| Vasserman, E | 1 |
| Nagler, A | 1 |
| Fabian, I | 1 |
| Gracia, E | 1 |
| Leiva, J | 1 |
| Oteiza, C | 1 |
| Liu, XG | 1 |
| Li, RC | 1 |
| Kaneko, Y | 1 |
| Kuroki, M | 1 |
| Ohi, H | 1 |
| Miyazaki, Y | 1 |
| Higashiyama, Y | 1 |
| Hirakata, Y | 1 |
| Tomono, K | 1 |
| Kadota, JI | 1 |
| Szabó, D | 1 |
| Máthé, A | 1 |
| Lengyel, J | 1 |
| Anderlik, P | 1 |
| Rókusz, L | 1 |
| Rozgonyi, F | 1 |
| Purswani, MU | 1 |
| Eckert, SJ | 1 |
| Arora, HK | 1 |
| Noel, GJ | 1 |
| Ciebieda, I | 1 |
| Korczak, E | 1 |
| Ferszt, T | 1 |
| Denys, A | 1 |
| Azoulay-Dupuis, E | 3 |
| Vallee, E | 3 |
| Veber, B | 1 |
| Bedos, JP | 2 |
| Bauchet, J | 1 |
| Pocidalo, JJ | 3 |
| Insler, MS | 3 |
| Stevens, RK | 1 |
| Paschal, JF | 1 |
| Phinney, RB | 1 |
| van Ogtrop, ML | 2 |
| Mattie, H | 2 |
| Sekh, BR | 1 |
| van Strijen, E | 1 |
| van Furth, R | 2 |
| Froidefond, S | 1 |
| Saivin, S | 1 |
| Lemozy, J | 1 |
| Marchou, B | 1 |
| Auvergnat, JC | 1 |
| Dabernat, H | 1 |
| Paulsen, DB | 1 |
| Corstvet, RE | 1 |
| McClure, JR | 1 |
| Enright, FM | 1 |
| McBride, JW | 1 |
| McDonough, KC | 1 |
| Sanders, CC | 1 |
| Hagenah, M | 1 |
| Bergogne-Bérézin, E | 1 |
| Roosendaal, R | 1 |
| van den Berghe-van Raffe, M | 1 |
| Vink-van den Berg, JC | 1 |
| Michel, MF | 1 |
| Chuard, C | 1 |
| Lucet, JC | 2 |
| Rohner, P | 2 |
| Herrmann, M | 2 |
| Auckenthaler, R | 2 |
| Waldvogel, FA | 2 |
| Lew, DP | 2 |
| Padeĭskaia, EN | 1 |
| Mnatsakanian, VE | 1 |
| Hardy, DJ | 2 |
| Swanson, RN | 2 |
| Cross, AS | 2 |
| Kelly, NM | 1 |
| Sadoff, JC | 2 |
| Bodmer, MW | 1 |
| Victor, GH | 1 |
| Girard, AE | 1 |
| Girard, D | 1 |
| Retsema, JA | 1 |
| Mayberry-Carson, KJ | 2 |
| Tober-Meyer, B | 2 |
| Gill, LR | 2 |
| Lambe, DW | 2 |
| Hossler, FE | 1 |
| Widmer, AF | 1 |
| Colombo, VE | 1 |
| Gächter, A | 1 |
| Thiel, G | 1 |
| Zimmerli, W | 1 |
| Dworkin, R | 1 |
| Modin, G | 1 |
| Kunz, S | 1 |
| Rich, R | 1 |
| Zak, O | 1 |
| Sande, M | 1 |
| Leibovitz, E | 1 |
| Keren, G | 1 |
| Shabtai, M | 1 |
| Barzilai, A | 1 |
| Rubinstein, E | 1 |
| Guiot, HF | 1 |
| Andriole, VT | 2 |
| Chadwick, M | 1 |
| Nicholson, G | 1 |
| Gaya, H | 1 |
| Collins, HH | 1 |
| Dobek, A | 1 |
| McClain, JB | 1 |
| Traub, WH | 1 |
| Hackbarth, CJ | 1 |
| Chambers, HF | 1 |
| Stella, F | 1 |
| Shibl, AM | 1 |
| Sande, MA | 2 |
| Peterson, LR | 2 |
| Moody, JA | 1 |
| Fasching, CE | 1 |
| Gerding, DN | 1 |
| Gargallo, D | 1 |
| Moros, M | 1 |
| Coll, R | 1 |
| Esteve, M | 1 |
| Parés, J | 1 |
| Xicota, MA | 1 |
| Guinea, J | 1 |
| Tudor, RG | 1 |
| Youngs, DJ | 1 |
| Yoshioka, K | 1 |
| Burdon, DW | 1 |
| Keighley, MR | 1 |
| Fitzgeorge, RB | 1 |
| Gibson, DH | 1 |
| Jepras, R | 1 |
| Baskerville, A | 1 |
| Mayberry, WR | 1 |
| Trautmann, M | 1 |
| Brückner, O | 1 |
| Marre, R | 1 |
| Hahn, H | 1 |
| Fernandes, PB | 1 |
| Chu, DT | 1 |
| Ramer, NR | 1 |
| Hanson, CW | 1 |
| Bower, RR | 1 |
| Stamm, JM | 1 |
| Neu, HC | 1 |
| Brooks-Fournier, RA | 1 |
| Gerberding, JL | 1 |
| Haller, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A National, Prospective, Randomized, Multicenter, Controlled Head-to-Head Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute in Filling of Contained Bone Defects[NCT00841152] | 120 participants (Actual) | Observational | 2009-03-31 | Completed | |||
| Bioactive Glass Granules as Bone Graft Substitute in Filling Material of Bone Defects[NCT01304121] | Phase 4 | 48 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for ciprofloxacin and Disease Models, Animal
| Article | Year |
|---|---|
Murine burn lesion model for studying acute and chronic wound infections.
Topics: Animals; Biofilms; Burns; Calgranulin A; Ciprofloxacin; Disease Models, Animal; Humans; Mice; Pseudo | 2022 |
Animal models for Francisella tularensis and Burkholderia species: scientific and regulatory gaps toward approval of antibiotics under the FDA Animal Rule.
Topics: Animals; Anti-Bacterial Agents; Burkholderia; Burkholderia Infections; Ciprofloxacin; Disease Models | 2013 |
The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy.
Topics: Administration, Inhalation; Administration, Intranasal; Animals; Anti-Bacterial Agents; Ciprofloxaci | 2014 |
US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax.
Topics: Adult; Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Child, Preschool; Ciprofloxacin; | 2004 |
Managing reactive arthritis.
Topics: Animals; Arthritis, Reactive; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Humans; Y | 2000 |
Review of preclinical studies with ofloxacin.
Topics: Animals; Bacteria; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Mic | 1992 |
Animal models: the in-vivo evaluation of ciprofloxacin.
Topics: Animals; Bacterial Infections; Ciprofloxacin; Disease Models, Animal | 1986 |
Efficacy of ciprofloxacin in animal models of infection.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Drug Ev | 1987 |
270 other studies available for ciprofloxacin and Disease Models, Animal
| Article | Year |
|---|---|
Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.
Topics: Administration, Inhalation; Aerosols; Animals; Anthrax; Anti-Bacterial Agents; Antibiotic Prophylaxi | 2007 |
Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Ciprofloxacin; Cricetinae; Disease Models, Animal; Do | 2007 |
Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Drug Resistance, | 2007 |
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
Topics: Anaerobiosis; Animals; Anti-Infective Agents; Bacterial Toxins; Cecum; Clostridioides difficile; Dis | 2007 |
Identification, biological activity, and mechanism of the anti-ischemic quinolone analog.
Topics: Animals; Anti-Bacterial Agents; Brain Ischemia; Cell Line, Tumor; Cell Survival; Disease Models, Ani | 2007 |
Kinetic studies and bioactivity of potential manzamine prodrugs.
Topics: Administration, Oral; Animals; Antimalarials; Candida albicans; Carbolines; Chlorocebus aethiops; Cr | 2008 |
Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
Topics: Administration, Inhalation; Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Disease Mod | 2008 |
Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis.
Topics: Animals; Disease Models, Animal; Esters; Female; Fluoroquinolones; Humans; Molecular Structure; Orga | 2008 |
Efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis in vitro and in an experimental model of actinomycetoma in BALB/c mice.
Topics: Animals; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Female; Fluoroquinolones; Mice; Mice, | 2009 |
Indolizidine, antiinfective and antiparasitic compounds from Prosopis glandulosa var. glandulosa.
Topics: Animals; Anti-Infective Agents; Antiparasitic Agents; Aspergillus fumigatus; Brain; Candida albicans | 2009 |
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; beta-Lactamases; beta-Lactams; Blood Pr | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological | 2010 |
Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Disease Models, Animal; Female; Lipoglycopeptides; | 2010 |
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
Topics: Adenosine Triphosphate; Animals; Anti-Bacterial Agents; Bacteria; Disease Models, Animal; DNA Topois | 2013 |
N-(1,3,4-oxadiazol-2-yl)benzamide analogs, bacteriostatic agents against methicillin- and vancomycin-resistant bacteria.
Topics: Animals; Anti-Bacterial Agents; Benzamides; Disease Models, Animal; Dose-Response Relationship, Drug | 2018 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
A Modular Synthetic Route Involving
Topics: Aniline Compounds; Animals; Anti-Bacterial Agents; Biofilms; Cell Line; Cell Survival; Disease Model | 2021 |
Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Survival; Cell Wall; Disease Models, Animal; Methicil | 2021 |
Repurposing Approved Drugs as Fluoroquinolone Potentiators to Overcome Efflux Pump Resistance in Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Carrier Proteins; Ciprofloxacin; Disea | 2021 |
Synergistic Effect of Co-Delivering Ciprofloxacin and Tetracycline Hydrochloride for Promoted Wound Healing by Utilizing Coaxial PCL/Gelatin Nanofiber Membrane.
Topics: Animals; Bandages; Cell Line; Ciprofloxacin; Disease Models, Animal; Drug Compounding; Drug Synergis | 2022 |
Duration of Ciprofloxacin Use Is Important in the Development of Abdominal Aortic Aneurysm in a Rat Model.
Topics: Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Ciprofloxacin; Disease Models, Animal; Male; | 2022 |
In vitro and in vivo evaluation of DNase I in reinstating antibiotic efficacy against Klebsiella pneumoniae biofilms.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Biofilms; Cattle; Cefotaxime; Ciprofloxacin; Deoxyribonucl | 2023 |
Design of Phage-Cocktail-Containing Hydrogel for the Treatment of
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Bacteriophages; Ciprofloxacin; Disease Models, | 2023 |
In vitro evaluation of Pseudomonas aeruginosa chronic lung infection models: Are agar and calcium-alginate beads interchangeable?
Topics: Agar; Alginates; Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; Lung; Pseudo | 2019 |
Successional Dynamics in the Gut Microbiome Determine the Success of
Topics: Animals; Anti-Bacterial Agents; Bacterial Shedding; Ciprofloxacin; Clindamycin; Clostridioides diffi | 2019 |
Evaluation of in vitro and in vivo antibiotic efficacy against a novel bioluminescent Shigella flexneri.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Cell Line; Ciprofloxacin; Disease Models, Animal; Dysent | 2019 |
DAV131A Protects Hamsters from Lethal
Topics: Administration, Oral; Adsorption; Animals; Anti-Bacterial Agents; Charcoal; Ciprofloxacin; Clostridi | 2019 |
Expression of T9W in Pichia pastoris and the protective roles of T9W in ICR Mice.
Topics: Animals; Anti-Infective Agents; Antimicrobial Cationic Peptides; Ciprofloxacin; Disease Models, Anim | 2020 |
Evaluation of liposomal ciprofloxacin formulations in a murine model of anthrax.
Topics: Administration, Intranasal; Animals; Anthrax; Bacillus anthracis; Ciprofloxacin; Disease Models, Ani | 2020 |
Development of a guinea pig inhalational anthrax model for evaluation of post-exposure prophylaxis efficacy of anthrax vaccines.
Topics: Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; Gu | 2020 |
Effect of Delaying Treatment on Efficacy of Ciprofloxacin and Levofloxacin in the African Green Monkey Model of Pneumonic Plague.
Topics: Animals; Anti-Bacterial Agents; Chlorocebus aethiops; Ciprofloxacin; Disease Models, Animal; Levoflo | 2020 |
In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Biofilms; Chemistry, Pharmaceutical; Cip | 2020 |
Antibiotics Act with vB_AbaP_AGC01 Phage against
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Bacteriolysis; Ba | 2020 |
Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Antigens, Bacterial; Bacillus anthracis; Bacterial Toxins; | 2021 |
Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Celecoxib; Ciprofloxacin; Dis | 2020 |
Bacteriophage-antibiotic combinations against ciprofloxacin/ceftriaxone-resistant Escherichia coli in vitro and in an experimental Galleria mellonella model.
Topics: Animals; Anti-Bacterial Agents; Bacteriophages; Biofilms; Ceftriaxone; Ciprofloxacin; Combined Modal | 2020 |
Kidney stone formation and the gut microbiome are altered by antibiotics in genetic hypercalciuric stone-forming rats.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Calcium; Ciprofloxacin; Disease Models, Animal | 2021 |
Multifunctional lipid-based nanocarriers with antibacterial and anti-inflammatory activities for treating MRSA bacteremia in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacteremia; Ciprofloxacin; Disease Models, | 2021 |
Ciprofloxacin and dexamethasone in combination attenuate S. aureus induced brain abscess via neuroendocrine-immune interaction of TLR-2 and glucocorticoid receptor leading to behavioral improvement.
Topics: Animals; Behavior, Animal; Brain Abscess; Ciprofloxacin; Dexamethasone; Disease Models, Animal; Drug | 2021 |
Deferiprone and Gallium-Protoporphyrin Have the Capacity to Potentiate the Activity of Antibiotics in
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Bacterial Load; Biofilms; Caenorhabditis el | 2017 |
Within-host spatiotemporal dynamics of systemic Salmonella infection during and after antimicrobial treatment.
Topics: Ampicillin; Animal Structures; Animals; Anti-Bacterial Agents; Bacterial Load; Blood; Ciprofloxacin; | 2017 |
Preclinical therapeutic efficacy of the ciprofloxacin-eluting sinus stent for Pseudomonas aeruginosa sinusitis.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Biofilms; Cells, Cultured; Ciprofloxacin; Disease Mo | 2018 |
High Intensity Focused Ultrasound (HIFU) Heating Improves Perfusion and Antimicrobial Efficacy in Mouse Staphylococcus Abscess.
Topics: Abscess; Animals; Anti-Bacterial Agents; Ciprofloxacin; Combined Modality Therapy; Disease Models, A | 2018 |
Ciprofloxacin-lidocaine-based hydrogel: development, characterization, and in vivo evaluation in a second-degree burn model.
Topics: Administration, Topical; Animals; Burns; Ciprofloxacin; Disease Models, Animal; Hydrogels; Lidocaine | 2018 |
Treating Anthrax-Induced Meningitis in Rabbits.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Antitoxins; Bacillus anthracis; Central Nervous System; Cip | 2018 |
Establishment of a drug-induced rhabdomyolysis mouse model by co-administration of ciprofloxacin and atorvastatin.
Topics: Acute Kidney Injury; Animals; Anti-Bacterial Agents; Aspartate Aminotransferases; Atorvastatin; Buth | 2018 |
Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice.
Topics: Animals; Anti-Bacterial Agents; Aorta, Thoracic; Aortic Aneurysm, Thoracic; Aortic Dissection; Cells | 2018 |
Ferulic acid derivative inhibits NorA efflux and in combination with ciprofloxacin curtails growth of MRSA in vitro and in vivo.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Biological Transport; Ciprofloxacin; Colony Coun | 2018 |
Lipid metabolism disorder induced by up-regulation of miR-125b and miR-144 following β-diketone antibiotic exposure to F0-zebrafish (Danio rerio).
Topics: Animals; Anti-Bacterial Agents; Atherosclerosis; Chlortetracycline; Cholesterol; Ciprofloxacin; Comp | 2018 |
Bioresponsive Nanoparticles Targeted to Infectious Microenvironments for Sepsis Management.
Topics: Amides; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Proteins; | 2018 |
Treatment of Streptococcus pneumoniae otitis media in a chinchilla model by transtympanic delivery of antibiotics.
Topics: Animals; Anti-Bacterial Agents; Chinchilla; Ciprofloxacin; Disease Models, Animal; Dose-Response Rel | 2018 |
Comparative Activity of Ceftriaxone, Ciprofloxacin, and Gentamicin as a Function of Bacterial Growth Rate Probed by Escherichia coli Chromosome Replication in the Mouse Peritonitis Model.
Topics: Animals; Anti-Bacterial Agents; Ceftriaxone; Ciprofloxacin; Disease Models, Animal; Escherichia coli | 2019 |
Comparative proteomics analyses of Acinetobacter baumannii strains ATCC 17978 and AB5075 reveal the differential role of type II secretion system secretomes in lung colonization and ciprofloxacin resistance.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Bacterial Proteins; Biofilms; Ciprofloxa | 2019 |
β-Glucan of Candida albicans Cell Wall Extract Inhibits Salmonella Typhimurium Colonization by Potentiating Cellular Immunity (CD8 + and CD4 + T Cells).
Topics: Animals; beta-Glucans; Candida albicans; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cel | 2019 |
Evolution and transmission of a conjugative plasmid encoding both ciprofloxacin and ceftriaxone resistance in Salmonella.
Topics: Animals; Anti-Bacterial Agents; Ceftriaxone; Ciprofloxacin; Disease Models, Animal; Drug Resistance, | 2019 |
Synergistic effect of immunomodulatory S100A8/A9 and ciprofloxacin against Pseudomonas aeruginosa biofilm in a murine chronic wound model.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Calgranulin A; Chronic Disease; Ciprofloxacin; Colony Coun | 2020 |
Microdialysis combined with liquid chromatography-tandem mass spectrometry for the quantitation of gemifloxacin and its application to a muscle penetration study in healthy and MRSA-infected rats.
Topics: Animals; Blood Proteins; Chromatography, Liquid; Ciprofloxacin; Disease Models, Animal; Gemifloxacin | 2019 |
Topics: Animals; Anti-Bacterial Agents; Cefotaxime; Ciprofloxacin; Colony Count, Microbial; Disease Models, | 2019 |
Effects of azithromycin in Pseudomonas aeruginosa burn wound infection.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Burns; Ciprofloxacin; Disease Models, Animal; Drug Syn | 2013 |
Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by Escherichia coli with or without the GyrA mutation Ser83Leu.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; Drug Resistance, | 2013 |
Chitosan-dextran sulphate nanocapsule drug delivery system as an effective therapeutic against intraphagosomal pathogen Salmonella.
Topics: Animals; Anti-Bacterial Agents; Cell Line; Chitosan; Ciprofloxacin; Dextran Sulfate; Disease Models, | 2013 |
Effects of combined treatment with ambroxol and ciprofloxacin on catheter-associated Pseudomonas aeruginosa biofilms in a rat model.
Topics: Ambroxol; Animals; Anti-Bacterial Agents; Biofilms; Catheters; Ciprofloxacin; Disease Models, Animal | 2013 |
Infective severe acute pancreatitis: a comparison of 99mTc-ciprofloxacin scintigraphy and computed tomography.
Topics: Animals; Biopsy; Chi-Square Distribution; Ciprofloxacin; Contrast Media; Disease Models, Animal; Esc | 2013 |
Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; Drug Administrati | 2013 |
BF-30 effectively inhibits ciprofloxacin-resistant bacteria in vitro and in a rat model of vaginosis.
Topics: Animals; Cathelicidins; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Bacterial; Escherich | 2014 |
PrtR homeostasis contributes to Pseudomonas aeruginosa pathogenesis and resistance against ciprofloxacin.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Bronchoalveolar Lavage | 2014 |
OTO-201: nonclinical assessment of a sustained-release ciprofloxacin hydrogel for the treatment of otitis media.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Chinchilla; Ciprofloxacin; Delayed-Action P | 2014 |
Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4.
Topics: Administration, Inhalation; Administration, Intranasal; Aerosols; Animals; Bacterial Vaccines; Biolo | 2014 |
Therapeutic potential of the antimicrobial peptide OH-CATH30 for antibiotic-resistant Pseudomonas aeruginosa keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antimicrobial Cation | 2014 |
Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever.
Topics: Administration, Inhalation; Administration, Intranasal; Animals; Anti-Bacterial Agents; Ciprofloxaci | 2014 |
Efficacy of purified lactonase and ciprofloxacin in preventing systemic spread of Pseudomonas aeruginosa in murine burn wound model.
Topics: Animals; Anti-Bacterial Agents; Burns; Chemokine CXCL2; Ciprofloxacin; Disease Models, Animal; Inter | 2015 |
In vitro and in vivo evaluation of novel ciprofloxacin-releasing silicone hydrogel contact lenses.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Coated Materials, Biocompatible; Contact Lenses, Exte | 2014 |
Enhanced virulence of the Escherichia coli O157:H7 spinach-associated outbreak strain in two animal models is associated with higher levels of Stx2 production after induction with ciprofloxacin.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; Disease Outbreaks; Escherichi | 2014 |
Azithromycin and ciprofloxacin: a possible synergistic combination against Pseudomonas aeruginosa biofilm-associated urinary tract infections.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bacterial Load; Biofilms; Ciprofloxacin; Cytokines; Di | 2015 |
Combatting bacterial infections by killing persister cells with mitomycin C.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Biofilms; Caenorhabditis elegans; Ciprofloxacin; Cross-L | 2015 |
[Prophylaxis of purulent complications in mechanical ileus].
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Biological Transport; Cephalosporins; Ciprofloxacin; Dis | 2015 |
Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anthrax; Anti-Bacterial Agents; Bacillus ant | 2015 |
Population Dynamics Analysis of Ciprofloxacin-Persistent S. Typhimurium Cells in a Mouse Model for Salmonella Diarrhea.
Topics: Animals; Ciprofloxacin; Dendritic Cells; Diarrhea; Disease Models, Animal; Humans; Lymph Nodes; Mice | 2016 |
Quercetin protection against ciprofloxacin induced liver damage in rats.
Topics: Animals; Antioxidants; Chemical and Drug Induced Liver Injury; Ciprofloxacin; Cytoprotection; Diseas | 2016 |
Ciprofloxacin plus erythromycin or ambroxol ameliorates endotracheal tube-associated Pseudomonas aeruginosa biofilms in a rat model.
Topics: Ambroxol; Animals; Anti-Bacterial Agents; Biofilms; Catheters, Indwelling; Ciprofloxacin; Disease Mo | 2015 |
Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography Study in Mice.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; | 2016 |
Exploiting the antivirulence efficacy of an ajoene-ciprofloxacin combination against Pseudomonas aeruginosa biofilm associated murine acute pyelonephritis.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Biofilms; Ciprofloxacin; Disease Models, Animal; Dis | 2016 |
Combined Therapy With Adipose-Derived Mesenchymal Stem Cells and Ciprofloxacin Against Acute Urogenital Organ Damage in Rat Sepsis Syndrome Induced by Intrapelvic Injection of Cecal Bacteria.
Topics: Adipose Tissue; Animals; Apoptosis; Bacteria; Biomarkers; Ciprofloxacin; Disease Models, Animal; Hum | 2016 |
Ciprofloxacin-loaded keratin hydrogels reduce infection and support healing in a porcine partial-thickness thermal burn.
Topics: Animals; Burns; Ciprofloxacin; Disease Models, Animal; Drug Carriers; Female; Hydrogels; Keratins; M | 2016 |
Co-administration of ginseng and ciprofloxacin ameliorates epididymo-orchitis induced alterations in sperm quality and spermatogenic cells apoptosis following infection in rats.
Topics: Animals; Anti-Bacterial Agents; Apoptosis; Ciprofloxacin; Disease Models, Animal; Epididymitis; Esch | 2017 |
Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3.
Topics: Animals; Antitubercular Agents; Bacterial Load; Bacterial Proteins; Biological Transport; Ciprofloxa | 2016 |
Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; Chromosomes, Bacterial; Ciprofloxacin; Disease Models, Animal; Esche | 2016 |
Dithiazole thione derivative as competitive NorA efflux pump inhibitor to curtail multi drug resistant clinical isolate of MRSA in a zebrafish infection model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Bacterial Proteins; Ciprofloxacin; Disease Models, A | 2016 |
Re: Combined Therapy with Adipose-Derived Mesenchymal Stem Cells and Ciprofloxacin against Acute Urogenital Organ Damage in Rat Sepsis Syndrome Induced by Intrapelvic Injection of Cecal Bacteria.
Topics: Adipose Tissue; Adiposity; Animals; Bacteria; Ciprofloxacin; Disease Models, Animal; Humans; Mesench | 2016 |
Low-dose norfloxacin and ciprofloxacin therapy worsen leptospirosis in hamster.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Biopsy; Ciprofloxacin; Cricetinae; Cytokines; Diseas | 2017 |
Effects of glucocorticoids in ventilated piglets with severe pneumonia.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bronchoalveolar Lavage; Ciprofloxacin; Diseas | 2008 |
Ocular poloxamer-based ciprofloxacin hydrochloride in situ forming gels.
Topics: Adhesiveness; Animals; Anti-Infective Agents; Biological Availability; Cellulose; Ciprofloxacin; Con | 2008 |
Pharmacokinetics of ciprofloxacin in normal rabbits and changes observed in induced dehydrated state.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Dehydration; Disease Models, An | 2008 |
Nona-D-arginine therapy for Pseudomonas aeruginosa keratitis.
Topics: Animals; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Ulcer; Disease Models, Animal; Drug | 2009 |
A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics.
Topics: Administration, Inhalation; Aerosols; Animals; Anthrax; Anti-Bacterial Agents; Bioterrorism; Ciprofl | 2009 |
Effect of ototopical ciprofloxacin-dexamethasone on myringotomy in a rat model.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Ciprofloxacin; De | 2009 |
Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Azithromycin; Cerebellum; Chi-Square Distribut | 2009 |
Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols.
Topics: Aerosols; Animals; Anti-Bacterial Agents; Antibodies, Bacterial; Antigens, Bacterial; Ciprofloxacin; | 2009 |
Auditory function after a prolonged course of ciprofloxacin-dexamethasone otic suspension in a murine model.
Topics: Acute Disease; Animals; Anti-Infective Agents; Ciprofloxacin; Dexamethasone; Disease Models, Animal; | 2009 |
[Bacterial corneal ulcer treated with intrastromal antibiotic. Experimental model in vivo].
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cornea; | 2009 |
Anti-inflammatory and antimicrobial effects of garlic and synergistic effect between garlic and ciprofloxacin in a chronic bacterial prostatitis rat model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Drug Synergism; Escherichia c | 2009 |
In vivo efficacy of sitafloxacin in a new murine model of non-typeable Haemophilus influenzae pneumonia by sterile intratracheal tube.
Topics: Animals; Anti-Bacterial Agents; Bronchioles; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones | 2009 |
The effect of topical ciprofloxacin and steroid-containing ear drops for chronic suppurative otitis media on the internal ear.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Audiometry; Chronic Disease; Ciprofloxacin; | 2010 |
Experimental studies on imaging of infected site with (99m)Tc-labeled ciprofloxacin in mice.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Isotope | 2009 |
Relationship between the expression of ompF and quinolone resistance in Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; Cell Growth Processes; Ciprofloxacin; Disease Models, Animal; DNA Gy | 2009 |
A novel antibiotic based long-term model of ovine smoke inhalation injury and septic shock.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Disease Models, Animal; Female; Nitric Ox | 2010 |
Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Colony Count, Mic | 2010 |
Antidiarrheal activity, chemical and toxicity profile of Berberis aristata.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Antidiarrheals; Berberine; Berberis; Ciproflox | 2011 |
Do Escherichia coli extract and cranberry exert preventive effects on chronic bacterial prostatitis? Pilot study using an animal model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Escherichia coli; Male; Pilot | 2011 |
The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension.
Topics: Animals; Anti-Bacterial Agents; Cannabinoid Receptor Modulators; Ciprofloxacin; Disease Models, Anim | 2011 |
Characterisation of a refined rat model of respiratory infection with Pseudomonas aeruginosa and the effect of ciprofloxacin.
Topics: Acute Disease; Agar; Animals; Anti-Infective Agents; Bacterial Load; Bronchoalveolar Lavage Fluid; C | 2011 |
Protective role for type-1 metabotropic glutamate receptors against spike and wave discharges in the WAG/Rij rat model of absence epilepsy.
Topics: Allosteric Regulation; Animals; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, D | 2011 |
Engineering and visualization of bacteria for targeting infarcted myocardium.
Topics: Animals; Arabinose; Blotting, Western; C-Reactive Protein; Ciprofloxacin; Disease Models, Animal; Dr | 2011 |
Effect of ciprofloxacin/dexamethasone versus ciprofloxacin/hydrocortisone on lipopolysaccharide-induced experimental otitis media.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chinchilla; Cipro | 2011 |
Post-exposure therapy of inhalational anthrax in the common marmoset.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Callithrix; Ciprofloxacin; Disease Mode | 2011 |
[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa].
Topics: Animals; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combinatio | 2011 |
Response to intracanal medication in immature teeth with pulp necrosis: an experimental model in rat molars.
Topics: Animals; Anti-Bacterial Agents; Apexification; Cementogenesis; Ciprofloxacin; Dental Pulp Necrosis; | 2011 |
Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Infective Agents; Blood Bactericida | 2011 |
Interaction between ciprofloxacin and chloroquine in mice infected with chloroquine resistant Plasmodium berghei: interaction between ciprofloxacin and chloroqune.
Topics: Animals; Antimalarials; Chloroquine; Ciprofloxacin; Disease Models, Animal; Drug Resistance; Drug Th | 2012 |
A novel post-exposure medical countermeasure L-97-1 improves survival and acute lung injury following intratracheal infection with Yersinia pestis.
Topics: Acute Lung Injury; Animals; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Combination; Humans | 2012 |
Ozone therapy prevents renal inflammation and fibrosis in a rat model of acute pyelonephritis.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Aspartate Aminotransferases; Calcitonin; Ciprofloxaci | 2011 |
Antibiotic control of tumor-colonizing Salmonella enterica serovar Typhimurium.
Topics: Animals; Anti-Infective Agents; Carcinoma; Ciprofloxacin; Colonic Neoplasms; Disease Models, Animal; | 2011 |
Evaluation of wound healing and antimicrobial potentials of Ixora coccinea root extract.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Chloramphenicol; Ciprofloxa | 2011 |
Novel rat model of tympanostomy tube otorrhea.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Cytokines; Dexamethasone; Disease Models, Animal; Eus | 2012 |
Evaluation of the effectiveness of topical ciprofloxacin and prednisolone in the prevention of myringosclerosis.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Ciprofloxacin; Di | 2012 |
Effect of antibiotic treatment on fat absorption in mice with cystic fibrosis.
Topics: Animals; Anti-Bacterial Agents; Bile Acids and Salts; Body Weight; Ciprofloxacin; Cystic Fibrosis; C | 2012 |
Lethality in a murine model of pulmonary anthrax is reduced by combining nuclear transport modifier with antimicrobial therapy.
Topics: Active Transport, Cell Nucleus; Animals; Anthrax; Anti-Infective Agents; Cell-Penetrating Peptides; | 2012 |
Peroral ciprofloxacin therapy impairs the generation of a protective immune response in a mouse model for Salmonella enterica serovar Typhimurium diarrhea, while parenteral ceftriaxone therapy does not.
Topics: Adaptive Immunity; Administration, Oral; Animals; Anti-Bacterial Agents; Ceftriaxone; Ciprofloxacin; | 2012 |
Critical appraisal of air pouch infection model in rats.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Dose-Re | 2012 |
Rifampicin-soaked silver polyester versus expanded polytetrafluoro-ethylene grafts for in situ replacement of infected grafts in a porcine randomised controlled trial.
Topics: Animals; Anti-Bacterial Agents; Aorta, Abdominal; Biocompatible Materials; Blood Vessel Prosthesis; | 2012 |
Quantitative PCR and in vivo efficacy of antibiotics in the treatment of Vibrio vulnificus infection in a mouse model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Bacteriological Techniques; Blood; Ceftriaxone; Cipr | 2012 |
Reply to: Novel rat model of tympanostomy tube otorrhea.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dexamethasone; Disease Models, Animal; Male; Middle E | 2012 |
Biofilm formation by Pseudomonas aeruginosa in solid murine tumors - a novel model system.
Topics: 4-Quinolones; Animals; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Colony Count, Microbial; Dise | 2012 |
Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Ciprofloxacin; Disease Models, Animal; Drug Resistan | 2012 |
A dermal phototoxicity study following intravenous infusion administration of ciprofloxacin hydrochloride in the novel microminipigs.
Topics: Animals; Ciprofloxacin; Dermatitis, Phototoxic; Disease Models, Animal; Female; Infusions, Intraveno | 2013 |
Effect of anti-adhesion barrier solution containing ciprofloxacin-hydrocortisone on abraded mucosa with otitis media.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; Drug | 2013 |
The Lon protease is essential for full virulence in Pseudomonas aeruginosa.
Topics: Animals; Cell Division; Ciprofloxacin; Disease Models, Animal; Gene Expression Regulation, Bacterial | 2012 |
Optimal treatment of systemic bacillus Calmette-Guérin infection: investigations in an animal model.
Topics: Animals; Cell Survival; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, Drug; Dru | 2002 |
Significance of low-level resistance to ciprofloxacin in Klebsiella pneumoniae and the effect of increased dosage of ciprofloxacin in vivo using the rat granuloma pouch model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Bacterial; G | 2002 |
Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Cells, Cultured; Ciprofloxacin; Crohn Disease; | 2002 |
Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia.
Topics: Animals; Bronchoalveolar Lavage Fluid; Ceftriaxone; Ciprofloxacin; Colony Count, Microbial; Disease | 2003 |
Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Disease Mode | 2003 |
Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Biofilms; Catheterization; Ciprofloxacin; Colo | 2003 |
Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Delayed-Action Preparations; Disease Models, Animal; | 2003 |
Different susceptibility of two animal species infected with isogenic mutants of Mycobacterium bovis identifies phoT as having roles in tuberculosis virulence and phosphate transport.
Topics: Animals; Bacterial Proteins; Base Sequence; Cattle; Ciprofloxacin; Disease Models, Animal; Female; G | 2003 |
Experimental study of clinafloxacin alone and in combination in the treatment of ciprofloxacin-susceptible and -resistant pneumococcal meningitis.
Topics: Animals; Cerebrospinal Fluid; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Bacterial; Dru | 2003 |
Treatment of experimental bacterial keratitis with topical trovafloxacin.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Biological Availability; Ciprofloxacin; Col | 2004 |
Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cecum; Ciprofloxacin; Clindamycin; Colony-For | 2004 |
A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Disease Models, Anim | 2004 |
Comparative efficacy of topical gatifloxacin with ciprofloxacin, amikacin, and clarithromycin in the treatment of experimental Mycobacterium chelonae keratitis.
Topics: Administration, Topical; Amikacin; Animals; Anti-Bacterial Agents; Ciprofloxacin; Clarithromycin; Co | 2004 |
Prevention and treatment of experimental osteomyelitis in dogs with ciprofloxacin-loaded crosslinked high amylose starch implants.
Topics: Absorbable Implants; Amylose; Animals; Anti-Infective Agents; Ciprofloxacin; Cross-Linking Reagents; | 2004 |
Efficacy of the latest fluoroquinolones against experimental Yersinia pestis.
Topics: Animals; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones; Gatifloxacin; Mice; Mice, Inbred B | 2004 |
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DN | 2005 |
Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Ulcer; Disea | 2005 |
Efficacy of ciprofloxacin-releasing bioabsorbable osteoconductive bone defect filler for treatment of experimental osteomyelitis due to Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Bone Cements; Ciprofloxacin; Coated Materials, Biocompatible; Diseas | 2005 |
Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model.
Topics: Administration, Topical; Animals; Anti-Infective Agents, Local; Cefazolin; Ciprofloxacin; Colony Cou | 2005 |
Inhibition of mutation and combating the evolution of antibiotic resistance.
Topics: Animals; Bacterial Proteins; Ciprofloxacin; Disease Models, Animal; DNA Damage; DNA, Bacterial; Drug | 2005 |
Synergistic effect between catechin and ciprofloxacin on chronic bacterial prostatitis rat model.
Topics: Animals; Anti-Infective Agents; Catechin; Chronic Disease; Ciprofloxacin; Colony Count, Microbial; D | 2005 |
Impact of residual and therapeutic doses of ciprofloxacin in the human-flora-associated mice model.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacteria, Anaerobic; Bacterial Infections; beta-Glucosidas | 2005 |
Pathologic alterations detected in acute pancreatitis induced by sodium taurocholate in rats and therapeutic effects of curcumin, ciprofloxacin and metronidazole combination.
Topics: Animals; Anti-Infective Agents; Antioxidants; Bacterial Translocation; Ciprofloxacin; Curcumin; Dise | 2005 |
Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomy.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Transplantat | 2005 |
Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Biofilms; Catheters, Indwelling; | 2005 |
In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Mi | 2005 |
Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in 60Co-gamma-photon-irradiated and sham-irradiated mice.
Topics: Administration, Oral; Animals; Anthrax; Anti-Bacterial Agents; Aza Compounds; Bacillus anthracis; Bl | 2005 |
Eradication of small intestinal bacterial overgrowth in the cystic fibrosis mouse reduces mucus accumulation.
Topics: Animals; Anti-Infective Agents; Bacteria; Ciprofloxacin; Cystic Fibrosis; Cystic Fibrosis Transmembr | 2006 |
A comparison of gatifloxacin to ciprofloxacin in the prophylaxis of Streptococcus pneumoniae in rabbits in a LASIK model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Cornea; Disease Models, Animal; Eye Infections, Bacte | 2006 |
Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, | 2006 |
The preparation of ciprofloxacin hydrochloride-loaded chitosan and pectin microspheres: their evaluation in an animal osteomyelitis model.
Topics: Animals; Anti-Infective Agents; Biocompatible Materials; Calorimetry, Differential Scanning; Chitosa | 2006 |
Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Microbial; D | 2006 |
Role of topical fluoroquinolones on the pathogenesis of diffuse lamellar keratitis in experimental in vivo studies.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Corneal Stroma; Disease Models, Animal; Endotoxins; F | 2006 |
Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Ciprofloxacin; Disease Models, Animal; | 2007 |
In vitro and in vivo testing of bioabsorbable antibiotic containing bone filler for osteomyelitis treatment.
Topics: Absorbable Implants; Animals; Anti-Infective Agents; Bone Substitutes; Ciprofloxacin; Disease Models | 2006 |
Interleukin-1, interleukin-6, and interleukin-10 responses after antibiotic treatment in experimental chronic Staphylococcus aureus osteomyelitis.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cefuroxime; Chronic Disease; Ciprofloxacin; Disease Models | 2006 |
Comparative trial of different anti-bacterial combinations with propolis and ciprofloxacin on Pseudomonas keratitis in rabbits.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Opacity; Dexamethaso | 2007 |
Effects of ciprofloxacin-dexamethasone on myringotomy wound healing.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dexamethasone; Disease Models, Animal; Drug Combinati | 2007 |
Effect of early and late antibiotic treatment in experimental acute pancreatitis in rats.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Cholagogues and Choleretics; Ciprofloxacin; Di | 2007 |
Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
Topics: Action Potentials; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Ani | 2007 |
The effects of methylene blue on renal scarring due to pyelonephritis in rats.
Topics: Animals; Anti-Infective Agents; Anti-Infective Agents, Urinary; Cicatrix; Ciprofloxacin; Disease Mod | 2007 |
Effect of experimentally induced Escherichia coli epididymo-orchitis and ciprofloxacin treatment on rat spermatogenesis.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Epididymitis; Escherichia col | 2007 |
Collagen bilayer dressing with ciprofloxacin, an effective system for infected wound healing.
Topics: Animals; Anti-Bacterial Agents; Cattle; Ciprofloxacin; Collagen; Disease Models, Animal; Infections; | 2007 |
Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Ulcer; Disease Model | 2007 |
A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis.
Topics: Administration, Topical; Animals; Anti-Infective Agents, Local; Cefazolin; Chlorhexidine; Ciprofloxa | 2007 |
Efficacy of ciprofloxacin implants in treating experimental osteomyelitis.
Topics: Absorbable Implants; Animals; Anti-Infective Agents; Biocompatible Materials; Blood Platelets; Body | 2008 |
Laparoscopic diagnosis and treatment of aortic vascular prosthetic graft infections in a porcine model.
Topics: Animals; Anti-Bacterial Agents; Aorta; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation | 2008 |
Synergistic effect between lycopene and ciprofloxacin on a chronic bacterial prostatitis rat model.
Topics: Animals; Anti-Bacterial Agents; Carotenoids; Ciprofloxacin; Colony-Forming Units Assay; Disease Mode | 2008 |
Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cytokines; Disease Models, Animal; Flu | 2008 |
Local treatment of experimental Pseudomonas aeruginosa osteomyelitis with a biodegradable dilactide polymer releasing ciprofloxacin.
Topics: Absorbable Implants; Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; Drug Imp | 2008 |
Efficacy of sustained release ciprofloxacin microspheres against device-associated Pseudomonas aeruginosa biofilm infection in a rabbit peritoneal model.
Topics: Absorption; Animals; Anti-Infective Agents; Biofilms; Ciprofloxacin; Delayed-Action Preparations; Di | 1995 |
Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Dexamethasone; Disea | 1995 |
Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of experimental Pseudomonas aeruginosa keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Ciprofloxacin; Cornea; Corneal Ulcer; Disea | 1994 |
[Comparative evaluation of the effectiveness of fluoroquinolones in experimental anthrax infection].
Topics: Animals; Anthrax; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Drug Evaluation, Pre | 1994 |
Comparative efficacy of topical ciprofloxacin for treating Mycobacterium fortuitum and Mycobacterium chelonae keratitis in an animal model.
Topics: Administration, Topical; Animals; Ciprofloxacin; Colony Count, Microbial; Disease Models, Animal; Ey | 1994 |
Efficacy of azithromycin for treating Babesia microti infection in the hamster model.
Topics: Animals; Antimalarials; Azithromycin; Babesiosis; Ciprofloxacin; Clindamycin; Cricetinae; Disease Mo | 1993 |
Comparison of topical antibiotics for treating Mycobacterium fortuitum keratitis in an animal model.
Topics: Administration, Topical; Amikacin; Animals; Ciprofloxacin; Clarithromycin; Colony Count, Microbial; | 1993 |
Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium.
Topics: Ampicillin Resistance; Animals; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Microbial; D | 1993 |
Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis.
Topics: Administration, Topical; Animals; Cefazolin; Ciprofloxacin; Colony Count, Microbial; Cornea; Disease | 1993 |
Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitis.
Topics: Animals; Aqueous Humor; Ciprofloxacin; Corneal Ulcer; Disease Models, Animal; Drug Therapy, Combinat | 1993 |
Evaluation of the efficacy of different antibiotics in inhibiting colonisation of Vibrio cholerae O1 in the rabbit intestine.
Topics: Animals; Anti-Bacterial Agents; Cholera; Ciprofloxacin; Disease Models, Animal; Evaluation Studies a | 1993 |
Impact of different classes antimicrobial agents on plasma endotoxin activity.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Blood Pressure; Cefotaxime; Cepha | 1996 |
Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Arthritis, Reactive; Body Weight; Ciprofloxa | 1996 |
Efficacy of ciprofloxacin and dexamethasone in experimental pseudomonas endophthalmitis.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Ciprofloxacin; Dexamethasone; Disease Mode | 1996 |
Determination of the in vivo post-antibiotic effects of ciprofloxacin and rifampicin.
Topics: Animals; Anti-Infective Agents; Antibiotics, Antitubercular; Ciprofloxacin; Disease Models, Animal; | 1995 |
Absorption of topically administered ciprofloxacin, ofloxacin and gentamicin in the inflamed rabbit eye.
Topics: Absorption; Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aqueous | 1996 |
Experimental posttraumatic Bacillus cereus endophthalmitis in a swine model. Efficacy of intravitreal ciprofloxacin, vancomycin, and imipenem.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacillaceae Infections; Bacillus cereus; Cipr | 1996 |
The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis.
Topics: Animals; Anti-Infective Agents; Benzalkonium Compounds; Chelating Agents; Ciprofloxacin; Colony Coun | 1996 |
Experimental Bacillus cereus post-traumatic endophthalmitis and treatment with ciprofloxacin.
Topics: Animals; Anti-Infective Agents; Bacillaceae Infections; Ciprofloxacin; Disease Models, Animal; Endop | 1996 |
Effect of 6-fluoro-8-methoxy quinolone (AM-1155) against chronic airway infection with Pseudomonas aeruginosa in a rat model.
Topics: Animals; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Disease Models, Animal; Fluoroquinol | 1997 |
The beneficial effects of ciprofloxacin on survival and hepatic regenerative activity in a rat model of fulminant hepatic failure.
Topics: Alanine Transaminase; Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; DNA; Im | 1998 |
Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection.
Topics: Animals; Antibiotic Prophylaxis; Ciprofloxacin; Disease Models, Animal; Doxycycline; Lung; Mice; Mic | 1998 |
Comparative therapeutic efficacy of clinafloxacin in a Pseudomonas aeruginosa mouse renal abscess model.
Topics: Abscess; Animals; Anti-Infective Agents; Area Under Curve; Ceftazidime; Cilastatin; Cilastatin, Imip | 1998 |
The efficacy of ciprofloxacin and doxycycline against experimental tularaemia.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Ciprofloxacin; Diseas | 1998 |
Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Dose-Re | 1998 |
Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Disease Models, Anim | 1998 |
In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants.
Topics: Animals; Anti-Infective Agents; Biocompatible Materials; Capsules; Ciprofloxacin; Disease Models, An | 1998 |
Treatment of chronic suppurative otitis media with topical ciprofloxacin.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Disease Mod | 1998 |
Recombinant human interleukin-11 in experimental Pseudomonas aeruginosa sepsis in immunocompromised animals.
Topics: Animals; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Com | 1998 |
Synoviocyte-packaged Chlamydia trachomatis induces a chronic aseptic arthritis.
Topics: Animals; Arthritis, Reactive; Bacterial Outer Membrane Proteins; Blotting, Western; Chlamydia Infect | 1998 |
Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia.
Topics: Acute Kidney Injury; Administration, Cutaneous; Animals; Anti-Infective Agents; Bacteremia; Ciproflo | 1999 |
Update on the experimental human model for chancroid infection.
Topics: Animals; Anti-Infective Agents; CD4 Lymphocyte Count; Chancroid; Ciprofloxacin; Disease Models, Anim | 2000 |
Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Toxins; Ciprofloxacin; Coliphages; | 2000 |
The role of the resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Biopsy; Body Weight; Chronic Disease; Ciprofloxacin; | 2000 |
Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations.
Topics: Animal Testing Alternatives; Animals; Anti-Infective Agents; Blood Platelets; Cattle; Ciprofloxacin; | 2000 |
An animal model for external ear canal inflammation.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Ciprofloxacin; De | 2000 |
[The chemotherapeutic efficacy of ciprofloxacin and lomefloxacin in the inhalation method of infecting white mice with tularemia].
Topics: Aerosols; Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Drug Evaluation, Pr | 2000 |
Is prophylactic ciprofloxacin effective in delaying biliary stent blockage?
Topics: Administration, Oral; Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Cats; Ciprofloxacin; C | 2000 |
Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Drug Carriers; Drug Delivery | 2001 |
Lack of antimicrobial activity of sodium heparin for treating experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock technique.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anticoagulants; Catheterization; Ciprofloxaci | 2001 |
Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-induced leukopenia.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Bone and Bones; Bone Marrow Cells; Cell Count; Ciprof | 2001 |
A simple infection model using pre-colonized implants to reproduce rat chronic Staphylococcus aureus osteomyelitis and study antibiotic treatment.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Biofilms; Cefuroxime; Cephalosporins; Chronic | 2001 |
Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice.
Topics: Absorption; Administration, Oral; Animals; Anti-Infective Agents; Antibiotics, Antitubercular; Cipro | 2001 |
Effects of parenterally administered ciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilator-associated pneumonia.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Cefozopran; Cephalosporins; Cilastatin; Ciprofloxa | 2001 |
In vitro and in vivo activities of ciprofloxacin and levofloxacin against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.
Topics: Animals; Anti-Infective Agents; beta-Lactamases; Ciprofloxacin; Colony Count, Microbial; Disease Mod | 2002 |
Effect of ciprofloxacin on lethal and sublethal challenge with endotoxin and on early cytokine responses in a murine in vivo model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Cytokines; Disease Models, Animal; Dose-Response Rela | 2002 |
[Effect of TFX (Polfa) on the course of experimental bacterial infections in mice treated with ciprofloxacin, amikacin and cefoperazone].
Topics: Amikacin; Animals; Cefoperazone; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, | 1992 |
In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Female; Fluoroquinolones; Leu | 1992 |
Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis.
Topics: Animals; Cefazolin; Ciprofloxacin; Colony Count, Microbial; Disease Models, Animal; Eye Infections, | 1992 |
Mycobacterium fortuitum keratitis. A comparison of topical ciprofloxacin and amikacin in an animal model.
Topics: Amikacin; Animals; Ciprofloxacin; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; | 1992 |
Methicillin-resistant Staphylococcus aureus keratitis in the rabbit: therapy with ciprofloxacin, vancomycin and cefazolin.
Topics: Animals; Cefazolin; Ciprofloxacin; Corneal Ulcer; Disease Models, Animal; Drug Therapy, Combination; | 1992 |
Comparison of the antibacterial efficacies of ampicillin and ciprofloxacin against experimental infections with Listeria monocytogenes in hydrocortisone-treated mice.
Topics: Ampicillin; Animals; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug A | 1992 |
[Resistance to antibiotic treatment produced in a model of experimental Pseudomonas aeruginosa peritonitis].
Topics: Amikacin; Animals; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Microbial; D | 1992 |
Use of an indwelling bronchial catheter model of bovine pneumonic pasteurellosis for evaluation of therapeutic efficacy of various compounds.
Topics: Animals; Anti-Infective Agents; Antibodies, Bacterial; Body Temperature; Bronchoalveolar Lavage Flui | 1992 |
Ciprofloxacin and prednisolone therapy for experimental Pseudomonas keratitis.
Topics: Administration, Topical; Animals; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Disease Mo | 1992 |
Pharmacokinetics of four fluoroquinolones in an animal model of infected lung.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones; Lung Diseas | 1991 |
Impact of the duration of infection on the activity of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.
Topics: Animals; Bacteremia; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Drug Administration Schedul | 1991 |
Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Diffusion Chambers, Culture; D | 1991 |
[Activity of fluoroquinolones studied on a model of suppurative meningoencephalitis caused by Pseudomonas aeruginosa in mice].
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Microbial; E | 1991 |
Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.
Topics: Amoxicillin; Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Erythromycin; Fe | 1991 |
Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Combination; Fl | 1990 |
Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa.
Topics: Agranulocytosis; Animals; Antibodies, Monoclonal; Ciprofloxacin; Combined Modality Therapy; Disease | 1990 |
Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Bacteroides fragilis; Ciprofloxa | 1990 |
Effect of ciprofloxacin on experimental osteomyelitis in the rabbit tibia, induced with a mixed infection of Staphylococcus epidermidis and Bacteroides thetaiotaomicron.
Topics: Animals; Bacteroides; Bacteroides Infections; Bone and Bones; Bone Marrow; Catheters, Indwelling; Ci | 1990 |
Salmonella infection in total hip replacement: tests to predict the outcome of antimicrobial therapy.
Topics: Adult; Amoxicillin; Animals; Arthritis, Infectious; Bacterial Adhesion; Ciprofloxacin; Diffusion Cha | 1990 |
Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis.
Topics: Animals; Chronic Disease; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Combination; Male; Me | 1990 |
The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model.
Topics: Abscess; Animals; Anti-Bacterial Agents; Ciprofloxacin; Colony Count, Microbial; Disease Models, Ani | 1989 |
Decontaminating efficacy of ciprofloxacin in an animal model.
Topics: Animals; Bacterial Infections; Cecum; Ciprofloxacin; Digestive System; Disease Models, Animal; Gastr | 1989 |
An update on the efficacy of ciprofloxacin in animal models of infection.
Topics: Abscess; Animals; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Endocarditis, Bacteri | 1989 |
Combination chemotherapy with ciprofloxacin for infection with Mycobacterium tuberculosis in mouse models.
Topics: Animals; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Combination; Isoniazid; Male; Mice; Ri | 1989 |
Oral ciprofloxacin and a monoclonal antibody to lipopolysaccharide protect leukopenic rats from lethal infection with Pseudomonas aeruginosa.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Ciprofloxacin; Combined Modality Therapy; Cyc | 1989 |
Chemotherapy of experimental (murine) Clostridium perfringens type A gas gangrene.
Topics: Animals; Ciprofloxacin; Clindamycin; Clostridium perfringens; Disease Models, Animal; Gas Gangrene; | 1988 |
Ciprofloxacin in experimental Pseudomonas aeruginosa meningitis in rabbits.
Topics: Animals; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Meningitis; Pseudomonas aeruginosa; Pse | 1986 |
In vivo and in vitro activity of ciprofloxacin plus azlocillin against 12 streptococcal isolates in a neutropenic site model.
Topics: Amikacin; Animals; Azlocillin; Ciprofloxacin; Disease Models, Animal; Drug Synergism; Drug Therapy, | 1987 |
Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.
Topics: Animals; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacteria; Chemical Phenomena; Chemis | 1988 |
A comparison of the penetration of two quinolones into intra-abdominal abscess.
Topics: Abdomen; Abscess; Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Disease Model | 1988 |
Studies on ciprofloxacin therapy of experimental Legionnaires' disease.
Topics: Administration, Oral; Animals; Ciprofloxacin; Disease Models, Animal; Drug Evaluation, Preclinical; | 1985 |
Effect of ciprofloxacin on subcutaneous abscesses induced with Staphylococcus epidermidis and a foreign body implant in the mouse.
Topics: Abscess; Animals; Ciprofloxacin; Disease Models, Animal; Foreign Bodies; Injections, Subcutaneous; M | 1988 |
Comparative efficacy of ciprofloxacin, ceftazidime and gentamicin, given alone or in combination, in a model of experimental septicemia due to Klebsiella pneumoniae in neutropenic mice.
Topics: Agranulocytosis; Animals; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Combinat | 1988 |
A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria.
Topics: Abscess; Animals; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacteroides Infecti | 1988 |
Ciprofloxacin: an overview and prospective appraisal.
Topics: Administration, Oral; Animals; Bacterial Infections; Ciprofloxacin; Cystic Fibrosis; Disease Models, | 1987 |
Efficacy of ciprofloxacin in animal models of infection: endocarditis, meningitis, and pneumonia.
Topics: Animals; Ciprofloxacin; Disease Models, Animal; Drug Evaluation, Preclinical; Endocarditis, Bacteria | 1987 |
Evaluation of ciprofloxacin alone and in combination with other antibiotics in a murine model of thigh muscle infection.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Drug In | 1987 |